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The last 20-25 years have seen an explosion of interest in the role of NADPH oxidase (NOX) in 
cardiovascular function and disease. In vascular smooth muscle and endothelium, NOX generates 
reactive oxygen species (ROS) that act as second messengers, contributing to the control of normal 
vascular function. NOX activity is altered in response to a variety of stimuli, including G-protein 
coupled receptor agonists, growth-factors, perfusion pressure, flow and hypoxia. NOX-derived ROS 
are involved in smooth muscle constriction, endothelium-dependent relaxation and smooth muscle 
growth, proliferation and migration, thus contributing to the fine-tuning of blood flow, arterial wall 
thickness and vascular resistance. Through reversible oxidative modification of target proteins, ROS 
regulate the activity of protein tyrosine phosphatases, kinases, G proteins, ion channels, cytoskeletal 
proteins and transcription factors. There is now considerable, but somewhat contradictory evidence 
that NOX contributes to the pathogenesis of hypertension through oxidative stress. Specific NOX 
isoforms have been implicated in endothelial dysfunction, hyper-contractility and vascular 
remodelling in various animal models of hypertension, pulmonary hypertension and pulmonary 
arterial hypertension, but also have potential protective effects, particularly NOX4. This review 
explores the multiplicity of NOX function in the healthy vasculature and the evidence for and against 






Vascular smooth muscle (VSM) function is regulated by a highly complex network of intracellular 
signalling pathways incorporating cell surface receptors, G proteins, ion channels/transporters, 
kinases/phosphatases, cytoskeletal proteins/adaptors, transcription factors, all under the regulation 
of endocrine, neuronal, paracrine/autocrine, metabolic and mechanical stimuli. For these stimuli to 
contribute effectively to vascular function, they must be able to induce the production of second 
messenger molecules and these must be able to influence the function of specific cellular targets in a 
pre-determined spacio-temporal manner, and these effects must be readily reversible. Established 
second messenger molecules include cytosolic Ca2+, cyclic nucleotides, phospholipids and more 
recently, reactive oxygen species (ROS). ROS can be defined as any electrophilic oxygen containing 
species, but in living cells, the primary species are superoxide (O2∙-) and its dismutation product 
hydrogen peroxide (H2O2), which are produced through one or two electron reduction of molecular 
oxygen, respectively. Electron transfer is catalysed by members of a large family of oxidoreductase 
enzymes. For many of these, including complex I and III of the mitochondrial electron transfer chain, 
uncoupled endothelial nitric oxide synthase (eNOS), xanthine oxidase, cyclooxygenases and 
lipoxygenases, ROS production is considered to be secondary to the principle function of the enzyme, 
at least under normal physiological conditions [1-7]. However, the main source of ROS in the 
vasculature (including in VSM and endothelium), is from the family of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases (NOX), for which their sole function is the production of 
superoxide and/or H2O2 [8-10]. In phagocytes the function of NOX is to generate an ‘oxidative burst’ 
the purpose of which is to kill and destroy engulfed pathogens. In non-phagocytic cells, including VSM 
and endothelium however, it is now known that NOX-derived ROS act as essential second messenger 
molecules contributing to the regulation of normal cellular function and their production is tightly 
regulated. Only during ‘oxidative stress’, a key feature of cardiovascular disease, are ROS produced in 
excess and considered harmful. Of the seven known isoforms of NOX, four are expressed in VSM and 
endothelium, namely NOX1, 2, 4, and 5.   
 
Experimental and theoretical analysis of the chemical properties of superoxide and H2O2 in aqueous 
or hydrophobic environments suggests that both of these ROS species can modify protein function 
though direct oxidation of the sulfhydryl side chains (-SH) of cysteine residues [11, 12], resulting in 
conformational changes that may enhance or inhibit protein activity. Single electron oxidation 
(sulfenylation; R-SOH) is readily reversible through the combined action of thioredoxins, glutathione 
peroxidases and reduced glutathione (GSH). Additional oxidation of –SOH (sulfinylation; R-SO2H) is 
also reversible through the action of sulfiredoxin-1, but further oxidation of –SO2H (sulfonylation; R-
SO3H) is considered irreversible [13-15]. Cysteine oxidation may also result in reversible formation of 
intra-molecular or inter-molecular disulphide bonds that stabilize a particular tertiary or quaternary 
structure, again to either promote or inhibit function. Under normal conditions, cysteine oxidation is 
highly selective, being dependent on the dissociation constant (pKa) of the sulfhydryl group in 
question and therefore its propensity to donate electrons. In addition to direct oxidation by ROS, 
cysteine residues may be oxidised indirectly by oxidised peroxyredoxin (PRX) or nitrosylated (R-SNO) 
by the reactive nitrogen species, nitric oxide (NO∙) [16, 17]. Nitrosylation requires a prior single 
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electron oxidation (R-S∙) and is reversible through the action of thioredoxin-1 and GSNO-reductase 
[17].  
Thioredoxin may also catalyse trans-nitrosylation of cysteine by nitroso-glutathione (GSNO) [17], or 
cysteine may be directly glutathionylated by oxidised glutathione (R-SSG). Recent work has also 
suggested that ROS-dependent oxidation of methionine (R-SCHO) may also influence protein and 
vascular function and this is reversible through the action of methionine sulfoxide reductase [18, 19]. 
Cysteine, lysine and histidine residues may also be modified through the formation of Michael adducts 
with lipid peroxides (LOO-) such as 4-hydroxynonenal, generated by oxidation of poly-unsaturated 
fatty acids. Being lipids, this latter form of modification may be of particular importance for the 
oxidative regulation of membrane bound proteins, such as ion channels [20].  
 
Superoxide spontaneously reacts with NO∙, to form peroxynitrite (ONOO-). ONOO- also modifies 
protein function by nitrating tyrosine residues (R-ONO), via reaction with CO2 and formation of the 
intermediate nitrogen dioxide and carbonate anion radicals, NO2∙ and CO3∙- [17]. Nitration influences 
protein function by preventing or mimicking phosphorylation [21]. In the presence of free cytosolic 
Fe2+, H2O2 is converted to the very powerful oxidant hydroxyl radical (OH) which oxidises proteins 
indiscriminately, regardless of pKa, thus is unlikely to be of physiological relevance. Key targets for 
reversible oxidative modification by NOX-derived ROS in VSM function include a wide range of cell 
surface and intracellular proteins, including phosphatases, kinases and other cytosolic enzymes such 
as G-proteins and adapter proteins, ion channels and transporters and transcription factors. 
 
This review will provide an update on expression, compartmentalisation, regulation and function of 
the different NOX isoforms expressed in the vasculature. It will detail the complex signalling networks 
both upstream of NOX activation and downstream of ROS production. It will report on how NOX 
activity is regulated by factors that influence VSM function, including vasoconstrictors, vasodilators, 
pressure/stretch, flow/shear-stress, mitogenic stimuli and hypoxia. Principle ROS effector proteins 
and downstream signalling pathways relevant to normal VSM function (contraction/relaxation) and 
the influence of endothelial factors on that function (NO∙, endothelium-derived hyperpolarising 
factor, EDHF) will be examined. Also included is a summary of how the expression and function of 
specific NOX isoforms is altered in hypertension, with often conflicting evidence for and against their 
importance to the pathogenesis of the disease. The role of NOX4 is particularly contentious. Finally, 
there will be a discussion of NOX function in the pulmonary circulation, how it differs from systemic, 
its importance to the pulmonary vasoconstriction response to acute hypoxia and its potential role in 
pulmonary hypertension.    
 
2. NADPH oxidase isoform expression and regulation in the vasculature 
2.1. NOX isoforms. The first identified and best characterised of the NADPH oxidases is the 
membrane-spanning flavocytochrome b558, a heterodimer composed of gp91phox (now known as 
NOX2), and p22phox. gp91phox is composed of six transmembrane -helices connected by five loops, 
three of which are extracellular and the other two intracellular, while p22phox is composed of two 
transmembrane -helices with cytosolic tails at both termini [22-24]. b558 generates superoxide by 
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the single electron reduction of two molecules of oxygen, the two electrons being transferred one at 
a time from a single molecule of NADPH at a dehydrogenase domain via FAD and two internally bound 
haem units [25]. This enzyme was identified as being responsible for the phagocytic respiratory burst 
in leucocytes [22], but soon after found to be expressed at considerably lower but functionally 
significant levels in both vascular smooth muscle cells (VSMCs) [26] and endothelium [27]. NOX2 
requires specific stimuli for full activation, and collectively the intracellular loops of gp91phox and 
p22phox interact with cytosolic regulatory subunits p47phox, p67phox and p40phox following a sequence of 
signalling events resulting in their translocation from the cytosol where they reside as a non-active 
heterotrimer [28]. 
 
The essential steps in the activation of the phagocytic oxidase begin with activation of protein kinase 
C (PKC) and PKC-dependent phosphorylation of the cytosolic regulatory subunit p47phox. This 
phosphorylation triggers cytosolic to membrane translocation of p47phox, together with other cytosolic 
regulatory subunits p67phox and p40phox, their association with gp91phox and p22phox and partial oxidase 
activation [29-31]. p67phox is thought to contribute to the dehydrogenation of NADPH and the transfer 
of e- to FAD [30, 32-34]. Full oxidase activity also requires phosphatidyl inositol-3 kinase (PI3K) and the 
small G proteins Rac1 or Rac2. PI3K is required mainly because p47phox and p40phox also possesses 
phosphoinositide binding sites [35-37], while Rac1 binds the dehydrogenase domain of gp91phox and 
p67phox and is required for complete assembly and full activation of the oxidase [22, 30, 38]. gp91phox 
also appears to require direct phosphorylation by PKC during its activation [39]. As detailed below, 
vascular NOX2 is activated in a similar way, although the specifics of how PKC, PI3K and Rac are 
activated and subcellular distribution of subunits may vary.    
 
There are now known to be seven isoforms of the catalytic subunit of NOX (NOX 1-5 and DUOX1 & 2), 
of which NOX 1, 2, 4 & 5 are expressed in the vasculature [23]. The relative abundance of NOX1 and 
NOX2 appears to vary depending on the cell type, size of vessel and vascular bed, as well as species 
and physiological/pathophysiological conditions [23, 26, 40-45]. Collectively, the literature suggests 
that both are expressed in both endothelium and VSMCs but NOX2 appears to be the dominant 
subtype in endothelium, while NOX1 predominates in VSMCs. NOX4 is ubiquitously expressed at high 
levels in both VSMCs and endothelium of humans and rodents [23, 45-53] and in one report, is 100-
fold more abundant in endothelium than NOX2 [53]. NOX5 is highly expressed in the human 
vasculature, but curiously absent from rodents [54-57]. All other NOX/phox subunits expressed in 
phagocytes are also present in VSMCs and endothelium [23, 26, 58-60]. As in phagocytes, p22phox is 
essential for G-protein coupled receptor (GPCR)-induced NOX1/2 activity in the vasculature [61-63]. 
As with NOX2, p47phox, p67phox, p40phox and Rac also participate in the activation of NOX1 [64], but 
vascular cells and tissues expressing NOX1 also express homologues of p47phox and p67phox, NOXO1 
and NOXA1, respectively [23](discussed further in section 2.3).  
 
Low levels of preassembled NOX1 or NOX2 [41, 60] together with active NOX4 [65] or NOX5 [66] 
probably contribute to basal ROS levels in unstimulated cells, and under these conditions, the rate 
limiting step for basal NOX-derived superoxide is probably the availability of cytosolic NADPH [67]. 
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This ‘basal’ ROS undoubtedly contributes to normal resting cellular functions such as basal eNOS 
activity and resting smooth muscle tone, as well as making a contribution to ROS-dependent protein-
folding in the endoplasmic reticulum [46, 51, 68-70].  However, NOX isoforms respond to external 
stimuli by generating brief bursts of ROS in the short term or sustained increases over longer periods. 
Over the short to medium terms (seconds to several minutes), enhanced NOX activity requires an 
initial stimulus which, through a series of signalling events, results in full activity of the enzyme. The 
exact nature of the stimulus, activation cascades and their effects depend largely on the NOX isoform 
being examined, its location in the cell and in which cell type it is expressed. As expected, acute stimuli 
for the production of ROS in VSM and/or endothelium include GPCR, flow/shear-stress, 
pressure/stretch and hypoxia, but also some growth factor and cytokine receptors (Table 1).  
2.2. NOX1 and NOX2 ‘Canonical’ activation pathway. GPCR agonists are the most frequently studied 
short term stimuli for NOX1 and NOX2 activity in the vasculature. The most extensively studied of the 
vascular GPCR agonists for NOX1 or NOX2 is angiotensin II (Ang II), acting via the type 1 angiotensin 
receptor (AT1R) to induce vasoconstriction, gene expression, growth, proliferation and migration [26, 
40, 43, 45, 55, 71-108], but there are many others known to activate NOX in VSMC or endothelium 
through similar if not identical signalling pathways. These include endothelin-1 (ET-1) [55, 84, 109-
114], ATP/purinergic agonists [64, 115-118], urotensin II [119-121], thrombin [62, 122-130], 
vasopressin [131], catecholamines (especially, alpha agonists) [131-137], 5-hydroxytryptamine (5-HT) 
[138], arachidonic acid and various eicosanoids, including prostaglandins, hydroxyeicosatetraenoic 
acids (HETEs) [6, 58, 139-146] and sphingolipids [147-150]. Here, common pathways for the activation 
of NOX in both VSM and endothelium are described. Additional activation by mechanical forces in the 
vasculature, most notably pressure/stretch in VSM and flow/shear-stress in endothelium, are 
discussed later.  
The multiple steps required to be taken to achieve full and complete activation of NOX1 or NOX2 in 
vascular tissue are similar to those that apply to the phagocytic oxidase in leukocytes and, as illustrated 
in Figure 1, can be divided into two phases: (1) a first phase, corresponding to an initial rapid, often 
transient elevation in ROS production, and (2) a second phase, corresponding to a sustained longer 
lasting increase in ROS production. The most important step in the first phase is the phosphorylation 
and translocation of p47phox to the membrane, together with recruitment of p67phox and p40phox and 
their association with NOX1/2 and p22phox. For this to occur, the initial stimulus must be capable of 
activating phospholipases C, D or A2 (PLC, PLD, PLA2) and the kinases PKC and/or Src, which then 
phosphorylate p47phox. The requisite step in the second phase is the recruitment of Rac to the partly 
assembled enzyme. Activation of Rac and complete assembly of the oxidase appears to require further 
ROS-dependent activation of Src and activation of PI3K, often via transactivation of a receptor tyrosine 
kinase (RTK), usually epidermal growth factor receptor (EGFR). Each of these key steps are outlined 
below. 
 
Phospholipase-dependent activation of PKC is an important first step in assembly of vascular NOX1 or 
NOX2 by GPCR agonists acting via Gq, although which phospholipase and which lipid products are 
considered most important for this activation appears to vary. Many GPCR expressed by VSMCs are 
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coupled to Gq and the activation of PLC, which generates inositol trisphosphate (IP3) and diacylglycerol 
(DAG). Conventional PKC isozymes are activated by Ca2+ released from IP3-sensitive stores and both 
conventional and novel isozymes are activated by DAG. Despite this, relatively few studies have 
directly shown NOX activation to be PLC-dependent in the vasculature. These include NOX2-
dependent ROS production induced by Ang II in renal preglomerular VSMCs [133] and NOX1-
dependent ROS production induced by sphingosylphosphorylcholine in mesenteric and pulmonary 
artery [148], sphingosine-1 phosphate (S1P) in rat aorta [147], advanced glycosylation end-products 
in retinal capillaries [151] or by thrombospondin-1 (TSP-1) in mouse aorta [152]. Alternatively, there 
is substantial evidence for a role of the PLD- or PLA2-derived lipids phosphatidic acid, arachidonic acid 
or lysoposphatidylcholine, in activation of NOX by GPCR. PLD and PLA2 are activated by G subunits 
[153, 154], while PLD activation in response to Ang II and other GPCR agonists also requires the small 
GTPase ARF6 [90, 108, 155]. In response to Ang II in VMSC, these lipid metabolites are likely to be 
activating PKC, since as outlined below, PKC-dependent serine phosphorylation of p47phox is a 
prerequisite for p47phox translocation to the membrane and its association with NOX1/2 and p22phox, 
although which PKC isozyme is specifically shown to be PLD or PLA2-dependent in this context is rarely 
specified [79, 80, 100, 156, 157]. Various stimuli In endothelium, including thrombin, low density 
lipoprotein and tumor necrosis factor- (TNF-) appear to couple PLA2–derived arachidonic acid 
metabolites to NOX activity [124, 158-160], and two of these stimuli are likely to involve PKC as the 
target of those metabolites [158, 159].   
 
There is strong evidence supporting a necessary role for PKC in NOX activation in VSM of multiple 
vascular beds and in some endothelial preparations, as demonstrated by the blocking effect of PKC 
inhibitors on NOX activity and ROS production in response to various stimuli including direct PKC 
activation by phorbol esters [67, 140, 161, 162]. These include Ang II in mouse and human coronary, 
human subcutaneous artery, rat aortic VSMCs and mouse renal preglomerular arterioles [77, 80, 100, 
133, 152, 163], TSP-1 in mouse aorta [152], TNF- or platelet-derived growth factor (PDGF) in human 
pulmonary endothelium and rat aortic VSMCs [158, 163], U46619 or sphingosylphosphorylcholine in 
bovine coronary, rat mesenteric or bovine aortic endothelium [6, 58, 140, 148] and direct PKC 
activators in rat or bovine aorta or bovine coronary artery [140, 156, 164]. Hypoxia is also capable of 
activating NOX via PKC [165] and is almost certainly doing so via upstream stimulation of mitochondrial 
ROS production (section 7.2), since PKC is also ROS-sensitive (section 3.3). Multiple studies have used 
p47phox-/- mice, siRNA or inhibitory peptides that target p47phox interaction with p22phox, gp91phox and/or 
NOX1 at the membrane to show the dependence of the initial stimulated ROS production on p47phox 
in the vasculature [72, 93, 97, 104, 118, 132, 140, 144, 148, 152, 158, 165-168]. As in phagocytes, 
several studies have confirmed that the main role of PKC in vascular NOX activation is to serine 
phosphorylate p47phox, triggering translocation of p47phox and p67phox to the membrane and their 
association with NOX and p22phox [6, 26, 58, 97, 118, 152, 158, 162, 169]. In addition, some studies 
have implicated specific PKC isozymes in vascular NOX activation, namely PKC- [162], PKC- [163, 
170, 171], PKC- [169], PKC- [148, 165] or PKC- [6, 108, 158]. There is also evidence for a role for 
phosphorylation of p22phox, p67phox and p40phox by a range of serine/threonine kinases in non-vascular 
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cells [22, 30, 172], much of which may also be relevant in the vasculature but is yet to be 
demonstrated.  
 
Interestingly, NOX activity in VSMCs and endothelium, unlike that in leukocytes, also appears to be 
dependent on tyrosine kinase activity, particularly the non-receptor tyrosine kinase Src, or other 
closely related kinases. Src is strongly involved in both pressor and vascular remodelling responses to 
Ang II and a range of other stimuli [101] and is strongly associated with ROS signalling in the 
vasculature eg. [173, 174] and reviewed in [175-177]. Multiple studies have used Src inhibitors, siRNA 
or Src-/- mouse to show the necessity of Src activity for either NOX1 or NOX2 activation in various 
vascular preparations, including bovine coronary artery VSMCs [140], rat or mouse mesenteric and 
pulmonary arteries [101, 148], renal preglomerular VSMCs [133], rat or mouse aortic VSMCs [77, 101], 
human coronary or subcutaneous arteries [82, 178] or human pulmonary endothelium [179]. Like PKC, 
activated Src can trigger p47phox translocation and initial NOX1/2 activation by direct tyrosine 
phosphorylation of p47phox [82, 140, 144, 179] or indirectly via phosphorylation and activation of PKC 
[173] which also phosphorylates p47phox, as described above. Interestingly, Src may also be activated 
by PKC-dependent phosphorylation [133, 140, 180, 181], resulting in positive feedback between the 
two kinases. This association between the two kinases is potentially initiated by basal ROS since both 
kinases are ROS sensitive [176, 177] (sections 3.2 and 3.3). A number of additional pathways have 
been suggested for the activation of Src by GPCR, including direct activation by G subunits [182, 
183]. Translocation of cytosolic subunits and NOX activation may also involve a degree of actin 
cytoskeleton re-organisation, via Src and/or PKC-dependent phosphorylation of actin-associated 
proteins. One study has suggested that before PKC- can phosphorylate and trigger the translocation 
of p47phox to the plasma membrane it must first phosphorylate smooth muscle-22 thus freeing itself 
from the actin cytoskeleton [169]. Others show in human VSMCs and endothelium that Src 
phosphorylates cortactin, facilitating phosphorylation of p47phox and its translocation to the 
membrane [85, 184, 185]. A third study has also suggested that translocation of p47phox and activation 
of vascular NOX1 is facilitated by binding of p47phox to ezrin-radixin-moesin binding phosphoprotein 
50 [89]. 
 
Once the holoenzyme is assembled at the plasma membrane, full activation of vascular NOX1 or NOX2 
also requires association of the catalytic subunit and p67phox with activated Rac1 or Rac2, as described 
above for the phagocytic oxidase. This has been shown for basal ROS and ROS production induced by 
GPCR agonists and growth factors in mouse, rodent and human VSMCs and bovine endothelium [62, 
71, 77, 90, 144, 178, 186, 187]. Being a small G-protein, Rac requires activation by Rac-specific guanine 
nucleotide exchange factors (RacGEFs). RacGEFs in turn require phospholipid binding and/or tyrosine 
phosphorylation for their activation. RacGEF tyrosine phosphorylation is Src-dependent, either direct 
or via intermediary activation of other non-receptor tyrosine kinases focal adhesion kinase (FAK), 
protein tyrosine kinase 2 (PYK2) or Janus kinase-2 (JAK2) [188-192]. In response to GPCR stimulation, 
Src also indirectly contributes to activation of the lipid kinase PI3K via phosphorylation and 
transactivation of growth factor receptors (particularly EGFR) [77, 125, 130, 145, 149, 193-195]. 
Subsequently, PI3K-derived phosphatidyl inositol bisphosphate (PIP2) and/or phosphatidyl inositol 
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trisphosphate (PIP3) promote translocation and activation of Rac1 and complete NOX complex 
assembly at the membrane [77, 96, 196]. PIP3 binds and activates multiple RacGEFs [197-199], while 
in neutrophils, but not yet shown in VSM or endothelium, PIP2 and PIP3 bind and provoke 
conformational changes in p47phox and p40phox thus promoting/stabilising NOX2 assembly [36, 37]. PIP2 
and PIP3 production is also supported by concomitant inhibition of the lipid phosphatase PTEN 
(phosphatase and tensin homolog) by the same stimuli that activate PI3K [142], perhaps by the initial 
NOX-derived ROS [196, 200] (see also section 3.1).  
 
Interestingly, a number of studies have shown that growth factor receptor transactivation and PI3K 
activation in vascular cells is also NOX-dependent [62, 149, 150]. A popular explanation for this is that 
partial activation of NOX generates sufficient ROS to further activate Src, promoting docking to and 
transactivation of the growth factor receptor and that the NOX/Src/EGFR/PI3K/Rac/NOX signalling 
axis constitutes multiple nested positive feedback loops between NOX1/2-derived ROS and ROS 
dependent signalling (particularly Src and PKC) [42, 77, 140]. Indeed, exogenously applied H2O2 
stimulates NOX activity in lysed VSMC membrane fractions [165]. It has been suggested that this 
feedback loop also forms the basis of the late sustained phase of ROS production which persists for at 
least 30 min after the initial GPCR-induced stimulus in VSMCs, following an EGFR-independent 
transient rapid phase [77]. Finally, GPCR-induced EGFR transactivation in VSMCs may also occur 
through direct oxidative activation of EGFR [200], ROS-dependent matrix metalloprotease activation, 
and epidermal growth factor shedding [130, 136, 201] or via oxidative inhibition of the tyrosine 
phosphatase Src-homology region-2 domain-containing phosphatase-2 (SHP2) [121, 200]. These are 
all parallel pathways which can probably operate independently of Src. Of relevance to downstream 
signalling, activated growth factor receptors also act as docking sites for the assembly of growth and 
proliferation signalling complexes, including growth-factor receptor bound protein-2 (GRB2) and 
PI3K/AKT (section 6.3).  
 
2.3. Other ‘non-canonical’ regulatory sub-units and NOX chaperones. NOX1 can form functional 
oxidase units at the membrane with NOXO1 instead of p47phox [202] and/or with NOXA1 instead of 
p67phox [126, 202, 203]. Unlike p47phox, NOXO1 lacks the auto-inhibitory domain and PKC binding site, 
so does not require phosphorylation for its membrane targeting and association with NOX1/p22phox, 
perhaps conferring a greater degree of constitutive activity to the oxidase than with p47phox [202], 
although NOX1 presumably still requires PI3K and Rac1 for full activity. Alternatively, NOX1 may also 
be activated by a combination of p47phox and NOXA1 [126, 203], indeed one study suggests that while 
human endothelium expresses p67phox, it is completely absent from rodent aortic VSMCs and replaced 
by NOXA1 [203], and it has also been noted that NOXA1 expression in VSMC is lower than that of other 
cytoplasmic activators of NOX, thus introducing a possible rate limiting step for NOX1 activation, but 
suggesting regulation of NOXA1 expression may be  a key way of altering ROS production in the long 
term [126]. Alternatively, in VSMCs, physical association between NOXA1 and NOX1 may be facilitated 
by direct PKC--mediated phosphorylation of NOX1 [163]. NOX2 may also be activated by NOXA1, but 
with lower affinity/efficacy than by p67phox [204]. NOX1/2 expression and activity are also positively 
regulated by protein disulphide isomerase (PDI) and heat-shock protein 90 (HSP90) in both 
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endothelium and VSM [205-207]. PDI forms a ROS-induced intermolecular disulphide bond with 
p47phox which is apparently necessary for NOX1 enzyme complex stability [208].  
 
2.4. Regulation of NOX4 in the vasculature. NOX4 is expressed in both endothelium and VSM and 
according to some reports, is the most highly expressed NOX in both cell types [209, 210].  Like NOX1 
and NOX2, NOX4 also possesses a dehydrogenase domain that requires FAD for the transfer of 
electrons to O2 [211], but it differs in that it usually makes H2O2 instead of superoxide, presumably by 
the direct transfer of two electrons to each O2 molecule rather than one to each of two O2 molecules 
[45, 212-215], but may instead make superoxide in some intracellular compartments [212, 216]. 
Despite some reports that NOX4 preferentially uses NADH over NADPH as an electron donor [216, 
217], other studies in isolated membrane preparations demonstrated a similar selectivity for NADPH 
as for other NOX isoforms [212]. Like NOX1 and NOX2, the catalytic subunit of NOX4 associates with 
p22phox and this binding is necessary for catalytic activity [213, 214, 216, 218, 219], but unlike NOX1 or 
NOX2, it does not require p47phox, p67phox, NOX01, NOXA1, p40phox or HSP90 for its activation [205, 
213], suggesting that it exhibits a high degree of constitutive activity and makes a major contribution 
to basal ROS production in the vasculature, particularly basal H2O2 [45, 46, 65, 211-213, 215, 216, 220].  
 
Detailed characterisation of signalling pathways for the acute activation of NOX4 is scarce, but there 
is certainly sufficient evidence to support the suggestion that it responds acutely to flow/shear-stress 
in endothelium [52] (section 5.1), GPCR and growth factor stimuli in endothelium [215, 221-223], and 
various GPCR agonists in VSM [45, 131, 224-226] (Table 2). Some studies suggest that NOX4 activity is 
supported by arachidonic acid [210, 224] the production of which is stimulated by some GPCR, but 
they disagree over whether NOX4 activation by this lipid is also dependent on Rac [223, 224, 227], as 
is the case with NOX1 and NOX2, or is entirely independent of it [210, 213, 222]. There is also 
disagreement over whether or not NOX4 responds to activators of PKC and therefore whether it 
requires serine/threonine phosphorylation for full activity [210, 216]. There is as yet no evidence that 
NOX4 activity is regulated by tyrosine phosphorylation. The only clearly defined cytosolic regulatory 
protein for NOX4 is polymerase delta interacting protein 2 (Poldip2), which is necessary for NOX4-
mediated H2O2 production in VSMC [226, 228-230] and is a known actin and integrin-associated 
protein [49]. These relatively simple interactions are summarised in Figure 2. NOX4 is also expressed 
in subcellular organelles, such as the sarcoplasmic reticulum, but whether it can respond to acute 
stimuli at this location is unknown (see below). 
 
2.5. Regulation of NOX5 in the vasculature. NOX5 is similar to other NOX isoforms in that it has six 
transmembrane domains, two hemes and a dehydrogenase domain that binds FAD and NADPH, but 
it is fully functional as an oxidase in the absence of both p22phox and any cytosolic regulatory subunits 
[231, 232], except perhaps for HSP90 which appears to be essential for the long-term stability of the 
enzyme complex [205, 233], perhaps by antagonising the enzymatic instability induced by caveolin in 
endothelial caveolae [234]. The primary site of acute regulation of NOX5 is an N-terminal cytosolic 
domain containing four EF hands that bind free Ca2+, as well as Ca2+-calmodulin binding domains, that 
collectively relieve oxidase auto-inhibition [235, 236]. As a result, NOX5-derived ROS production is 
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enhanced by stimuli that raise intracellular Ca2+ concentration ([Ca2+]i) in endothelium and VSM, such 
as thrombin, Ang II, ET-1, U46619 and bradykinin, acting both via voltage-dependent extracellular Ca2+ 
influx and sarcoplasmic reticulum Ca2+-induced Ca2+ release [55, 66, 232, 237]. NOX5 is therefore 
essentially constitutively active but with a ‘basal’ activity that is dependent on [Ca2+]i [66]. However, 
in addition to this basal activity, the sensitivity of vascular NOX5 to increases in [Ca2+]i may also be 
enhanced via phosphorylation by kinases such as PKC- [238, 239], Ca2+-calmodulin activated kinase-
II (CAMK-II) [240], ERK-MAP kinase [241] or c-Abl [242], but inhibited by the Ca2+-independent PKC- 
[239]. These various routes for the activation of NOX5 are illustrated in Figure 2. Since H2O2 elevates 
[Ca2+]i (sections 4.2 and 4.3), NOX5 activation may also contribute to a positive feedback loop between 
multiple NOX isoforms [242], although this has yet to be demonstrated in vascular cells. 
 
2.6. Compartmentalisation of NOX isoforms and ROS metabolism. Since ROS are generally highly 
reactive species, it has been suggested that for them to operate as effective selective second 
messenger molecules, the site of ROS production should be localized near to or in the same sub-
cellular compartments as the target proteins or even be in direct contact with those target proteins in 
the same compartment. There is a growing body of evidence to support this [15, 48, 243-246]. As 
described above, all NOX isoforms expressed in the vasculature are located in the plasma membrane, 
but most are likely concentrated in or around specific structures on the cell surface. In VSM, plasma 
membrane NOX4 preferentially localises with vinculin and clustered integrins [48, 234], where 
presumably Poldip2 couples NOX4-derived ROS to activation of FAK, integrin-linked kinase (ILK) and 
RhoA at focal adhesions [49, 226, 229, 230, 247]. This may suggest a possible role for NOX4 in 
pressure/stretch-induced myogenic contraction (section 4.6) and VSM migration and proliferation 
(section 6.3). In endothelium, NOX1 and 2 are found in caveolae where they will associate with and 
be activated by the ‘mechanosome’ of the endothelial flow/shear-stress sensor. NOX5 is also located 
in caveolae, but is not known to be activated by flow. NOX4 is sensitive to flow but unlike NOX1, 2 and 
5, it is not located in the caveolae of endothelial cells and therefore caveolin cannot influence its 
activity in the short term, but it does negatively regulate its expression [234]. In caveolae, NOX1, 2 and 
5 are maintained in a resting state by caveolin-1 through disruption of the enzyme complex until this 
is relieved by HSP90 [205, 233]. NOX4 is presumably located elsewhere on the surface of endothelial 
cells, but to which structures it binds is unknown. The role of endothelial cell surface NOXs in sensing 
flow is discussed in more depth later in this review (section 5.1).  
 
Due to the orientation of NOX catalytic subunits in the plasma membrane, they will be producing 
primarily extracellular ROS. However, NOX4-derived H2O2 is free to diffuse through the plasma 
membrane to have intracellular actions, and this may be facilitated by cell surface aquaporins, widely 
expressed in the cardiovascular system [248-250] while for the negatively charged superoxide 
generated by NOX1, 2 or 5 to also have intracellular actions, transport must be facilitated by plasma 
membrane anion channels, including the chloride channel ClC-3 [251] and the volume sensitive 
channel LRRC8A [252], or it must first be dismutated to H2O2 by extracellular superoxide dismutase 
(SOD) [15, 253]. Alternatively, it is now fairly well established that functional NOX enzymes are also 
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located within various subcellular organelles, including the endosomes, sarcoplasmic reticulum, 
nucleus and mitochondria. 
 
It is well known that growth factor receptors, cytokine receptors and GPCR are endocytosed upon 
ligand binding or following transactivation in the case of RTKs, either to be recycled back to the plasma 
membrane or sent to lysosomes for degradation. However, it is also now known that key signalling 
events occur in the endosome following receptor activation [243, 252]. It has been suggested that this 
includes activation of NOX1 in VSM [130, 252, 254, 255], and for activation of NOX2 in endothelium 
[256, 257]. This appears to occur following endocytosis of the activated NOX enzyme together with 
the activating receptor. For NOX1 and NOX2, this may be facilitated by p40phox-dependent interaction 
with phosphoinositides in the endosomal membrane [36] or NOX-dependent phosphorylation of 
dynamin or caveolin-1 [252]. NOX4 and NOX5 are also found in endosomes and therefore may also 
contribute to endosomal RTK or GPCR signalling [242, 258]. Also endocytosed are several associated 
activator and effector proteins, such as Src, Rac and tyrosine phosphatases [245, 255, 258, 259]. 
Endosomes also contain SOD1, so superoxide can be dismutated to H2O2, enabling both NOX-derived 
ROS species to contribute to cell signalling in the endosome as a ‘redoxosome’ [15, 245, 246, 254, 257, 
258, 260]. Alternatively, there is evidence that endosomal superoxide may be released into the cytosol 
through volume-sensitive anion channels (LRRC8) [252] or ClC-3 [254, 255, 261] and of course, H2O2 is 
also free to diffuse into the cytosol.  
 
NOX4 is also co-expressed with p22phox in the sarcoplasmic reticulum of endothelium and VSM [46, 51, 
53, 219, 225] and probably generates ROS within the lumen of the organelle [219]. The H2O2 produced 
here is also free to diffuse out or exit the compartment via aquaporins [15], but specific functions for 
NOX-derived ROS within the endoplasmic reticulum have been considered. In particular, it may 
contribute to the oxidising environment required for normal disulphide-dependent protein folding 
[15, 68] or contribute to the oxidative modification of Ca2+ release channel function (section 4.3). 
NOX5 is also expressed in the endoplasmic reticulum of endothelium [232], but its functions there are 
unknown. A functional splice variant of NOX4 lacking transmembrane domains but which still 
associates with p22phox has been detected in the nucleus of VSMCs where it may directly contribute to 
oxidative regulation of gene expression [216, 262, 263]. NOX4 is also reportedly expressed in the 
mitochondria of cardiac myocytes [264, 265], but whether it is also expressed there in VSM or 
endothelium and what its function may be is unclear. The mitochondria also generates superoxide 
through leakage of electrons from the inner membrane electron transport chain [1, 2] and this is of 
particular functional importance in vascular responses to hypoxia, where it may be coupled to plasma 
membrane or endosomal NOX activity (sections 7.2 and 7.3). Movement of ROS from within 
mitochondria and sarcoplasmic reticulum into the cytosol is also facilitated by aquaporins and ClC-3 
(or equivalent) [15]. 
 
The multiple feedforward and positive feedback loops between ROS and upstream signalling pathways 
derived from NOX1 or NOX2 will ensure the response to a stimulus is rapid and amplifiable, but for 
this to be of any use as a controllable cell signal and to contribute to the highly compartmentalised 
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nature of the response there must also be an ‘off-switch’. For feedback involving Src and PKC it has 
been suggested that this may arise out of the fact that as well as being activated by ROS, the two 
kinases are also inactivated by ROS, but the latter perhaps only at higher concentrations [176, 244, 
266]. Apart from this, cells possess powerful antioxidant enzyme systems capable of limiting the 
accumulation and diffusion of any ROS generated and to some extent these too are 
compartmentalised. If superoxide does not react with target proteins or with NO∙ to produce ONOO-, 
then it will eventually be dismutated to H2O2. Superoxide dismutase is present in the cytosol and 
endosomes (SOD1) [260], mitochondria (SOD1, MnSOD/SOD2) and extracellular space (EC-SOD) [15]. 
While H2O2 is more freely diffusible and less reactive than superoxide, its ultimate complete reduction 
to H2O is catalysed by cytosolic catalase, or by peroxiredoxins or glutathione peroxidases located in 
the cytosol, mitochondria and endoplasmic reticulum [15]. The action of glutathione peroxidase is 
supported by the main cellular REDOX buffer, reduced glutathione (GSH). Oxidised glutathione (GSSG) 
is re-reduced to GSH by glutathione reductase utilising NADPH, which is itself generated in the pentose 
phosphate pathway, the ultimate source of cellular reducing equivalents. The compartmentalisation 
and metabolism of ROS are illustrated in Figure 3.  
 
3. Proximal targets for NOX-derived ROS in the vasculature. 
A wide range of signalling proteins involved in vascular smooth muscle function have been identified 
as being sensitive to ROS and often particularly sensitive to NOX-derived ROS. For many of these, the 
target protein is probably not directly sensitive to cysteine oxidation but is responding to ROS-induced 
modulation of an upstream ‘proximal ROS target’. Downstream effector pathways include multiple 
protein kinases, ion channels, guanine nucleotide exchange factors for small G-proteins of the Rho 
family, cytoskeletal proteins and transcription factors. Their roles in NOX-dependent vascular function 
will be detailed in subsequent sections. This section will focus on essential proximal ROS sensors, 
protein tyrosine phosphatases (PTPs) and non-receptor tyrosine kinases (NRTKs), as well as PKC and 
CAMK-II. 
 
Tyrosine phosphorylation has long been known as an essential early signalling event in response to 
growth factors and cytokines, since growth factor receptors are themselves tyrosine kinases and 
cytokine receptors directly activate non-receptor tyrosine kinases as an essential early step in their 
signalling cascades [21, 191, 267, 268], but more recently it has also been shown that vascular smooth 
muscle pro-contractile stimuli, GPCR agonists in general, stretch in many vascular beds and hypoxia in 
the pulmonary circulation, are also associated with enhanced total cellular tyrosine phosphorylation 
in the vasculature [21, 103, 269-273] and reviewed in: [176, 177]. Enhancements in cellular tyrosine 
phosphorylation induced by either growth or contractile stimuli in VSM are inhibited by antioxidants 
[267, 274, 275] or SOD and/or catalase [267, 276] and altered by inhibition/over-expression of NOX 
[103, 259, 274, 277, 278]. Similarly, exogenous ROS cause an increase in tyrosine phosphorylation in 
vascular tissues [103, 174, 191, 273, 279-283]. Net tyrosine phosphorylation and thus relative activity 
of the phosphorylated target proteins will always be determined by the relative opposing activities of 
tyrosine phosphatases and kinases [284]. For example, tyrosine phosphatase inhibitors generally 
induce constriction in vascular smooth muscle, whereas tyrosine kinase inhibitors induce relaxation 
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[82, 273, 279, 283]. As discussed in previous sections, all the stimuli mentioned above induce NOX-
derived ROS production in the vascular wall, therefore the observed NOX-dependent effects of ROS 
on net tyrosine phosphorylation are most likely occurring via the combined effects of ROS-induced 
PTP inhibition and ROS-induced NRTK activation. As discussed below, there is a direct link between 
the induced NOX activity and the stimulation of downstream contractile and mitogenic effector 
pathways.  
 
3.1. Protein tyrosine phosphatases. Tyrosine phosphatases, dual-specific phosphatases and the lipid 
phosphatase PTEN share a unique signature motif HC(X)5R(S/T) containing a nucleophilic cysteine 
which confers an unusually low pKa for ionization of 4-5 compared to the typical pKa of nonreactive 
cysteines of 8.5 in most other proteins [285]. Oxidation usually results in the formation of an 
intramolecular disulphide or sulfenamide bond which inhibits phosphatase activity by preventing 
docking to protein targets and relief of auto-inhibition. Like most serine threonine phosphatases, 
reduced PTPs (under low ROS conditions) do not require external stimuli for their activation and will 
be constitutively active when bound to target phospho-proteins, but will be progressively inactivated 
when cells are stimulated to increase ROS production, [196, 244, 286-290]. In some cases, as with 
PTEN, the phosphatase is protected from oxidation by PRX, but oxidation of PRX results in disulphide 
formation and inactivation of the phosphatase [16]. This oxidative inhibition is readily reversible 
through the action of glutathione peroxidase or thioredoxin [268, 288, 290].  
 
Key tyrosine phosphatases important in the control of VSM or endothelial function that are sensitive 
to NOX-derived ROS include SHP2 [121, 291], PTP1B (tyrosine protein phosphatase non-receptors type 
1) [51, 276], protein tyrosine phosphatase-M (PTPM) and low molecular weight protein tyrosine 
phosphatase (LMW-PTP) [292, 293]. All of these are key negative regulators of growth factor receptors 
and the signalling complexes that are activated by them. SHP2 is particularly important in suppressing 
activity of EGFR and platelet-derived growth factor receptor (PDGFR), by dephosphorylating phospho-
tyrosines essential for the docking and activation of PI3K and GRB2. This may occur in endosomes co-
expressing growth factor receptors and NOX1 or NOX4 and contributes to the feedback between RTK 
transactivation, PI3K activity and NOX activation [258]. PTP1B negatively regulates vascular 
endothelial growth factor receptor (VEGFR) signalling in endothelium [276] and appears to co-localise 
with NOX4 and EGFR in the endoplasmic reticulum where oxidative inhibition of the phosphatase 
promotes EGFR trafficking [51]. There is also some evidence that dual-specific tyrosine/threonine 
phosphatases are ROS-sensitive. This class of phosphatase is responsible for the de-phosphorylation 
and inactivation of MAP kinases and the oxidative inactivation of MAP kinase phosphatase-1 
contributes to MAP kinase activation in VSM [294]. As mentioned above, oxidative inhibition of PTEN 
contributes to NOX1/2 activation by supporting PI3K-derived PIP2 and PIP3 production [196], although 
this has yet to be directly demonstrated in vascular tissues. PIP3 is also required for the activation of 
AKT, thus PTEN is a possible route through which ROS may promote VSM growth. Obviously, 
phosphatases will oppose the actions of kinases by dephosphorylating downstream target proteins, 
such as ion channels, guanine nucleotide exchange factors and other kinases, but PTPs also de-
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phosphorylate tyrosine residues on kinases themselves and these phospho-tyrosines may be 
inhibitory or stimulatory of kinase activity. Indeed most tyrosine kinases possess both (See below).  
 
3.2. Receptor and non-receptor tyrosine kinases. There are two major families of tyrosine kinase, the 
receptor tyrosine kinases (RTK) and the non-receptor tyrosine kinases (NRTK). A feature shared by all 
tyrosine kinases is that they require auto-phosphorylation for full kinase activity. Most growth factor 
receptors are RTKs, and auto-phosphorylation is triggered by agonist binding and receptor 
dimerization or by transactivation involving phosphorylation by another kinase, usually an NRTK such 
as Src, in response to other stimuli, usually GPCR. This generates phospho-tyrosine docking sites for 
multiple downstream signalling pathways, including PI3K, GRB2 and PLC-. There are multiple families 
of NRTK, including the Src family kinases (notably Src, Fyn & Yes in vascular tissues), FAK, the closely 
related PYK2 and Janus kinase (especially JAK2). These kinases are important for mediating growth 
factor and cytokine-induced gene expression and growth-related signalling but are also key regulators 
of smooth muscle electrical excitability, intracellular Ca2+ and actin cytoskeleton dynamics, and 
therefore contractility. All of the above have, in one way or another, been implicated in ROS-
dependent signalling in the vasculature and are either upstream or downstream of NOX-dependent 
ROS production, and make a major contribution to the control of smooth muscle tone induced by 
GPCR agonists [133, 174, 176, 177, 272, 295, 296], stretch [194] and hypoxia [174, 271, 297] (section 
7.2), or the control of VSM proliferation [95, 298-300] (section 6.3).  
 
Src (the principle member of the Src-family kinases) is one of a handful of protein kinases known to 
be directly ROS-sensitive, although the majority of evidence for this stems from extensive work in non-
vascular cells and tissues. Src possesses two key phospho-tyrosine residues, an inhibitory one on the 
C-terminal tail (Y527 in humans) and a stimulatory one on the kinase activation loop (Y418 in humans). 
When Y527 is phosphorylated by c-Src kinase (CSK), internal SH2 binding promotes folding of the 
kinase, hiding the active site, and disruption of this internal binding by de-phosphorylation of Y527, or 
PKC-directed serine phosphorylation of the SH2 domain, triggers auto-phosphorylation of Y418, fully 
activating the kinase [301, 302]. Src also contains several reactive cysteine residues, including one in 
the SH2 domain and one in the kinase domain, oxidation of which induces hyper-phosphorylation of 
Y418 [303], and/or intermolecular disulfide bridge formation that may prevent internal Y527/SH2 
binding, thus prolonging kinase activity [304]. Oxidation of these two cysteine residues and Src 
activation occurs in response to NOX activation [305]. ROS may also module Src activity indirectly via 
oxidative inhibition of CSK and PTPs that de-phosphorylate Y418 (stimulatory of Src) or of PTPs that 
dephosphorylate Y527 (inhibitory of Src). The former may ensure a rapid response to and positive 
feedback to NOX activation, while the latter may contribute to a timely termination of the signal [301, 
306-308]. In line with Src activity generally having a positive relationship with NOX1/2-derived ROS 
generation, there is evidence that exogenous ROS activate Src and that VSM contractile or 
proliferative stimuli induce ROS-dependent or NOX-dependent Src oxidation and auto-
phosphorylation [125, 173, 174, 259, 303, 309-312], and stimuli that activate NOX-dependent 
contractile responses and contractions induced by exogenous ROS are both suppressed by inhibitors 




Several other NRTKs, including FAK, PYK2 and JAK2, are ROS sensitive in the vasculature, but unlike 
Src, are probably not directly ROS-sensitive. The likeliest route is downstream of Src, which 
phosphorylates these kinases, triggering stimulatory auto-phosphorylation [145, 309, 313-315]. 
Alternatively, it may occur downstream of oxidative inhibition of a PTP that de-phosphorylates their 
activation loop [189, 291], or phosphorylation by a ROS sensitive PKC [316]. Either way, they are 
activated by GPCR agonists and other contractile, migratory or mitogenic stimuli in a manner 
dependent on NOX and endogenous ROS production or by exogenous ROS [109, 110, 126, 189, 191, 
229, 309, 317, 318]. A couple of these studies have implicated specific NOX isoforms in activation of 
NRTK: JAK2 is stimulated by PDGF via NOX5-derived ROS [317] while FAK is activated by PDGF at focal 
attachments in a NOX4/Poldip2 dependent manner [229] and subsequently phosphorylates multiple 
focal adhesion associated proteins [319]. As discussed earlier, transactivation of growth factor 
receptors such as EGFR, PDGFR and insulin-like growth factor receptor (IGFR) is generally considered 
to be indirectly NOX and ROS-sensitive because the NRTK (usually Src) that initially phosphorylates the 
receptor in response to NOX activation is itself ROS-sensitive, as discussed above [125, 173, 194, 309]. 
As far as can be determined, only one study also suggests that EGFR transactivation may also involve 
direct sulfenylation of the EGFR kinase domain [200]. 
 
3.3. Protein kinase C and Ca2+-calmodulin-activated kinase II. PKC is a family of 12 cytosolic 
serine/threonine kinases and like Src, it appears to be both upstream of NOX activation and a directly 
ROS-sensitive NOX effector. Six PKC isozymes of three classes are expressed in vascular tissues: 
conventional (PKC-, -1, -2), novel (PKC- and -) and atypical (PKC-) [320, 321]. All PKC isozymes 
are inactive when maintained in a folded configuration due to a regulatory domain containing an auto-
inhibitory pseudo-substrate, which prevents access of the catalytic domain to substrate proteins. 
Unfolding and release of the pseudo-substrate is normally induced by Ca2+ ( and  only), DAG (   
and  only), other lipid mediators (all isozymes) and by tyrosine phosphorylation (all isozymes). Src is 
a key NRTK activator of PKC; reviewed in: [173, 176, 321]. Essential to the release of the pseudo-
substrate are multiple cysteine residues in the regulatory domain and these are also highly sensitive 
to intramolecular disulphide bridge formation [322]. Cysteine oxidation removes the requirement for 
Ca2+, or lipid mediators, automatically triggering unfolding and activation of the kinase [176, 321]. 
There is also evidence that cysteine residues on the catalytic domain of PKC may also be sensitive to 
oxidation, but that this oxidation inhibits kinase activity [323]. However, this appears to require higher 
concentrations of ROS than oxidation of regulatory domain cysteine residues, so may contribute to 
the termination of the positive feedback between PKC and NOX once sufficient ROS have been 
generated [176, 323] (section 2.6). These biochemical studies were all performed in non-vascular 
systems, but are supported by studies in vascular tissues showing that PKC undergoes cytosolic to 
membrane translocation and is activated in response to exogenous ROS in VSM or endothelium [324-
327] and that inhibition of specific PKC isozymes inhibits ROS-induced or ROS-dependent GPCR 
mediated contraction and associated signalling events in isolated arteries [148, 283, 325-327]. CAMK-
II is another kinase that is potentially both upstream (specifically of NOX5) and downstream of ROS. 
This kinase is normally activated by Ca2+-calmodulin, binding of which triggers autophosphorylation at 
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Thr287, but is also activated by oxidation of two methionine residues (Met281/282). This oxidative 
activation is maintained independently of Ca2+, but has the same effect on kinase activity [19, 328].  
 
4. Role of NOX in VSM contraction. 
VSM constriction negatively influences tissue blood flow while positively influencing vascular 
resistance and perfusion pressure. Thus, in order to match blood flow to the metabolic demands of 
the tissue, prevent tissue damage due to over-perfusion, contribute to thermoregulation and 
inflammation, or to regulate total peripheral resistance and MAP, VSM tone is under the control of 
circulating hormones (eg Ang II), peripheral neurotransmitters (noradrenaline, acetylcholine), 
paracrine and autocrine factors (bradykinin, histamine etc) haemodynamic forces (pressure/stretch, 
flow/shear-stress) as well as products of metabolism and PO2. Interestingly, NOX and the two principle 
ROS, superoxide and H2O2, contribute to both contraction and relaxation responses in the vasculature, 
depending on the vascular beds and the nature of the stimulus. This has in part been investigated by 
testing the effects of application of exogenous H2O2 and artificially generated intracellular superoxide 
with xanthine/xanthine oxidase or cell permeable quinones such as LY83583 or menadione [329, 330] 
(Table 3). Despite being considered somewhat of a blunt instrument due to the use of potentially 
supra-physiological concentrations and the loss of subcellular compartmentalisation [244], the results 
of such experiments are largely supported by pharmacological and genetic manipulation of specific 
NOX isoforms as well as the use of non-specific antioxidants and highly selective antioxidant enzymes 
(SOD and catalase). There are several effector pathways through which ROS influence VSM contraction 
and relaxation, acting on both the VSM and the endothelium. The simplest is by a shift in the balance 
between the availability of eNOS-derived NO∙ and NOX-derived superoxide in favour of superoxide 
and/or a change in the ability of SOD to remove superoxide. This results in more superoxide chemically 
reacting with and ‘scavenging’ NO∙, generating the poor vasodilator ONOO-, thus impairing 
endothelium-dependent relaxation and enhancing vascular tone [99, 102, 152, 331-333]. However, 
this mechanism by no means fully accounts for the observed effects of superoxide in the vasculature 
because inhibiting or ablating eNOS does not abolish the effect [137, 311, 334-336]. The alternatives 
are more complex. As discussed throughout this section and illustrated in Figures 4 and 5, ROS can 
induce phosphorylation of myosin-light chain-20 (MLC20), a necessary step in actin-myosin cross-
bridge cycling and contractile force generation, either by directly influencing VSM [Ca2+]i, which 
induces phosphorylation of MLC20 by myosin light-chain kinase (MLCK), or by inhibition of myosin light-
chain phosphatase (MLCP). There is also some evidence for a role in MLC20-independent effects on 
actin dynamics. In the following sections, evidence for the role of specific NOX isoforms in mediating 
contractile and relaxation stimuli will be discussed. Please note that many of the studies cited in the 
following sections have made use of pharmacological agents designed as specific inhibitors of NOX, 
such as apocynin, DPI and VAS2870, but which have subsequently been queried as non-specific 
flavoprotein inhibitors or even as general antioxidants rather than NOX inhibitors, particularly 
apocynin [337, 338]. Nevertheless, such studies are included here because they are by and large 
supported by parallel studies utilising specific NOX isoform/regulatory subunit siRNA, over-expression 
and knock-out/knock-in mouse models, as well as newer NOX inhibitors and antioxidant enzymes. 
Conclusions drawn from these studies are also corroborated by the parallel use of ROS measurement 
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and/or exogenous ROS, often in the same articles. Please see Tables 2 & 4 for an overview of the 
relevant literature in this regard.     
 
4.1. Pro-contractile actions of exogenous ROS. In the absence of pre-constriction, superoxide directly 
constricts rat aorta [339] and rat pulmonary artery [311, 340], but not mesenteric or femoral artery 
[311]. In the absence of pre-constriction, H2O2 directly constricts mouse and rat aorta [131, 341-344], 
bovine coronary artery [194], canine cerebral artery [283], mouse carotid [342] and rat or rabbit 
pulmonary artery [146, 326, 340, 343, 343, 345-347], but may or may not directly constrict rat 
mesenteric artery [341, 341-343, 348, 348]. In various mammalian systemic arterial preparations pre-
constricted with GPCR agonists or myogenic tone, both superoxide and H2O2 appear to exert mixed, 
concentration-dependent, contraction/relaxation effects [311, 325, 327, 334, 343, 349, 350], although 
the dominant effect of H2O2 tends to be relaxation (section 5). Superoxide consistently enhances 
GPCR-induced pre-constriction in pulmonary artery [174, 311, 351] (section 7.1.). Alternatively, in 
various mammalian systemic vascular preparations, both H2O2 and superoxide consistently enhance 
sub-maximal contraction induced by KCl [148, 341, 342, 344, 350-354], because KCl removes the 
influence of ROS on K+ channels (as explained further in section 5.5). Note that in some studies, 
superoxide generating systems X/XO or LY83583 reportedly cause contraction that is largely 
suppressed by SOD or only partly suppressed by catalase, suggesting that the contractile effect of 
superoxide does not necessarily require conversion to H2O2 [311, 339, 340, 351]. It is also worth 
highlighting that vasoconstriction in various vascular beds induced by exogenous ROS is inhibited by 
non-specific tyrosine kinase inhibitors [283, 341, 346], specific blockers of Src family kinases [174, 311, 
352], and PKC inhibitors [283, 325, 326], suggesting that these proximal kinases contribute to ROS-
induced VSM contraction either as direct ROS-sensors or downstream of PTP inhibition. There is 
evidence supporting a role for NOX-derived ROS, as well as Src and/or PKC, in all three of the main 
VSM contraction effector pathways (an increase in [Ca2+]i, inhibition of MLCP and actin 
polymerisation).  
 
4.2. NOX/ROS-dependent Ca2+ influx pathways. Smooth muscle contraction is primarily dependent 
on phosphorylation of MLC20 by the Ca2+-calmodulin-dependent MLCK. Exogenous H2O2 and 
superoxide applied in the absence of pre-constrictor agents induce increases in [Ca2+]i, in aorta and 
cerebral or mesenteric arteries [131, 283, 325, 348], while in pulmonary artery, H2O2 does [326], but 
superoxide does not [311]. However, superoxide does enhance GPCR-induced Ca2+ responses in 
pulmonary artery [351]. A major source of this ROS-induced [Ca2+]i response appears to be influx via 
L-type voltage-gated Ca2+ channels (LVGCC), particularly in systemic vessels. This is based partly on the 
inhibitory effects of specific LVGCC antagonists on exogenous ROS-induced [Ca2+]i and contraction in 
aorta and cerebral, mesenteric and renal arteries [283, 325, 327, 344, 348, 354, 355] and the 
enhancement of whole-cell L-type Ca2+ currents in mesenteric artery VSMCs by superoxide [148] and 
in cerebral artery by H2O2 [105]. NOX-derived endogenous ROS also contribute to GPCR-induced [Ca2+]i 
influx and contraction in part via enhanced opening of LVGCC. For example, in bovine pulmonary 
artery VSMCs, the U46619-induced [Ca2+]i increase is partially sensitive to inhibition of either NOX1/2 
or LVGCC [58], Ang II-induces apocynin or catalase-sensitive Ca2+ sparklets and contraction in rat 
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cerebral artery [105, 325] and sphingosylphosphorylcholine induces antioxidant-sensitive voltage-
gated Ca2+ current in mesenteric artery VSMCs in association with p47phox-dependent contraction 
[148]. In addition, mouse mesenteric artery expressing human NOX5 exhibit enhanced antioxidant-
sensitive contraction induced by depolarisation with sub-maximal KCl [66]. It is not clear whether cell 
surface NOX4 regulates Ca2+ channel activity in VSM but it does activate transient receptor potential 
canonical-6 (TRPC6) in podocytes in response to Ang II stimulation [356].  
 
There is conflicting evidence over the influence of ROS on LVGCC activity through direct cysteine 
oxidation or S-nitrosylation, some suggesting that it is stimulatory [357, 358] and others that it is 
inhibitory [359-362], perhaps depending on which region of the channel is targeted. Alternatively, 
ROS-dependent stimulation of LVGCC Ca2+ influx may be indirect, either via oxidative activation of 
protein kinases that activate the channel by phosphorylation, or via prior action on other membrane 
channels that depolarises the plasma membrane, thus opening LVGCC. VSM LVGCC open probability 
is increased by both serine/threonine and tyrosine phosphorylation, most probably PKC, CAMK-II 
and/or Src-mediated, because the pore-forming subunit of LVGCC (CaV1.2) is a phosphorylation target 
for all three kinases [325, 358, 363-365]. PKC- contributes to Ang II-induced NOX-dependent 
induction of LVGCC Ca2+ sparklet activity and contraction in rat cerebral artery [325]. CAMK-II 
enhances H2O2 induced CaV1.2 current in ventricular myocytes [358]. While there is no direct evidence 
that Src phosphorylates CaV1.2 in response to ROS, it is a reasonable assumption, considering it is itself 
a key ROS target in VSM. Conceivably, ROS could depolarise VSM by either inhibiting K+ channel activity 
or enhancing the activity of non-selective cation channels. One study suggests that LVGCC were being 
opened in response to ROS-dependent voltage-gated K+ channel (KV) inhibition and subsequent 
depolarisation [58]. However this response may be specific to the pulmonary vasculature (section 7.2), 
while a number of other studies in systemic vessels suggests that KV channel activity in VSM is 
enhanced by ROS, contributing to a pro-relaxant effect [350, 351, 366] (section 5.5). Alternatively, ROS 
are more likely to depolarise VSM through the opening of Ca2+-activated Cl- channels or TRP channels, 
which themselves also conduct Ca2+ [327]. In aortic VSMCs, GPCR agonists induce inward Ca2+ currents 
and contraction that are dependent on both TRPC6 and NOX (probably 1 or 2) and these effects are 
mimicked by exogenous H2O2 [131, 367]. In rat pulmonary artery, H2O2 enhances TRPC1/Stim1/Orai1-
dependent Ca2+ influx [368], and Ca2+-sensing receptor/TRPC6-dependent Ca2+ influx [369], while in 
renal afferent arterioles superoxide activates Ca2+-activated Cl- channels to enhance myogenic tone  
[327]. As with LVGCC, ROS are likely to be activating these channels indirectly via intracellular 
signalling, perhaps dependent on PLC/DAG and/or PKC [327, 367, 370]. There is also some evidence, 
albeit primarily from cardiac muscle, that  the plasma membrane Ca2+ ATPase is inhibited by ROS, a 
pro-contractile effect [13], while the Na+/Ca2+ exchanger may be activated, opposing this effect [13, 
371]. 
 
4.3. NOX/ROS-dependent Ca2+ store handling. Most VSM GPCR are coupled to Gq to stimulate 
production of IP3, so will trigger Ca2+ release from the sarcoplasmic reticulum via the IP3 receptor 
(IP3R). However, they may also open IP3R indirectly via NOX-derived ROS, since both exogenous and 
NOX-derived superoxide in VSM and endothelium appear to directly sensitize IP3R to IP3, increasing 
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the rate of stimulated Ca2+ release [372, 373]. Alternatively, H2O2-induced contractile responses in 
aorta and pulmonary artery are partially dependent on sarcoplasmic reticulum Ca2+ release via 
ryanodine sensitive channels (RyR) [326, 344]. In addition, many GPCR agonists induce RyR-dependent 
Ca2+ release, usually secondary to nearby Ca2+ influx or release by other sarcoplasmic reticulum 
channels such as the Two-Pore channel or IP3R (Ca2+-induced Ca2+ release). Of the three subtypes 
(RyR1, 2 and 3), RyR1 is probably pro-relaxant in systemic blood vessels ([374], but may be pro-
contractile in others [326], whereas RyR2 is universally considered pro-contractile [375]. All three 
subtypes are known to be directly ROS sensitive, containing multiple reactive cysteine residues that 
are important for channel activity [13, 376]. However, the functional significance of this has not been 
demonstrated in VSM. Instead Ang II-induced, RyR-mediated, sarcoplasmic reticulum Ca2+ release in 
renal afferent arterioles and pulmonary artery is indirectly dependent on NOX2 and also perhaps 
NOX4, via ROS-dependent production of CD38-derived cyclic ADP-ribose (cADPR) and nicotinic acid 
adenine dinucleotide phosphate (NAADP), activators of the RyR and Two-Pore channel, respectively 
[377-379]. In addition, vascular RyR2 may also be activated by ROS-induced dissociation of the 
inhibitory FKBP12.6 protein [375]. Ca2+ is pumped back into the sarcoplasmic reticulum by the 
sarcoplasmic reticulum Ca2+ ATPase (SERCA), and there is evidence that SERCA activity is suppressed 
by direct irreversible cysteine oxidation [13, 380], thus prolonging increases in [Ca2+]i. Recent evidence 
suggest that this oxidation of SERCA, albeit in cardiac muscle, may be mediated by NOX4-derived ROS 
in the sarcoplasmic reticulum [381]. It is not known whether NOX5 expressed in the sarcoplasmic 
reticulum contributes the regulation of Ca2+ homeostasis. The role of NOX-derived ROS in VSM Ca2+ 
influx and Ca2+ release signalling pathways is summarised in Figure 4. 
 
4.4. NOX/ROS-dependent, Ca2+-independent contractile signalling. In parallel with Ca2+-dependent 
activation of MLCK, there is also concomitant inhibition of MLCP which further enhances MLC20 
phosphorylation and contraction independently of a change in [Ca2+]i, a process that is often termed 
‘Ca2+-sensitization’ [382]. In line with this, exogenous ROS induce contraction in permeabilised, Ca2+-
clamped rat pulmonary artery [311, 326, 343, 351], and a high concentration of superoxide also does 
so in non-permeabilised arteries without raising [Ca2+]i  [311]. The main signalling pathway in VSM for 
inhibition of MLCP is phosphorylation of myosin phosphatase targeting subunit-1 (MYPT1) by Rho-
activated kinase (ROCK) [382, 383]. ROCK is a serine threonine kinase that exists in a folded inactive 
form in the cytosol until activated by the monomeric G-protein RhoA [384]. Prior to this, RhoA is 
activated by the exchange of bound GDP for bound GTP, a process usually catalysed by Rho-specific 
guanine nucleotide exchange factors (RhoGEFs).  
 
Contractions elicited by exogenous superoxide in rat aorta and pulmonary artery are blocked by 
inhibition of ROCK and are independent of dismutation to H2O2 [114, 311, 339, 351]. Sub-cellular 
translocation of ROCK, ROCK-mediated phosphorylation of MYPT1 and subsequent MLC20 
phosphorylation, are all induced by exogenous superoxide [176, 311, 339, 351]. Although there is no 
evidence that Rho-kinase is directly ROS-sensitive, exogenous superoxide causes cytosolic to 
membrane translocation of RhoA in rat aorta and pulmonary artery [174, 176, 339]. This may be 
because RhoA is directly ROS sensitive, as it contains reactive cysteine residues that when oxidised 
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mimic the effect of RhoGEF binding, lowering the affinity for guanine nucleotides and triggering 
exchange of GDP for GTP [385, 386]. Alternatively, ROS may activate RhoA and ROCK upstream of 
RhoGEF activation, since superoxide induced contraction in rat pulmonary artery is suppressed by 
RhoGEF inhibition [174]. Such a pathway probably involves tyrosine phosphorylation of the RhoGEF 
by ROS-sensitive NRTKs. Src is a prime candidate, being directly ROS-sensitive and important for GPCR 
and superoxide-induced RhoGEF translocation, RhoA translocation and/or MYPT1 phosphorylation in 
rat afferent arterioles and pulmonary artery [106, 133, 174, 272, 311]. Src is also known to activate 
RhoGEFs indirectly via other tyrosine kinases FAK, PYK2 or JAK2 [145, 313, 314]. Once activated, RhoA 
also directly promotes actin polymerisation and, via ROCK and LIM kinase, inhibits the actin severing 
protein cofilin [387]. There are two main physiological contractile stimuli that may activate RhoGEFs 
and subsequently activate RhoA and ROCK via NOX-derived ROS. GPCR directly activate RhoGEFs via 
G12/13, but also activate NOX1 or NOX2, and the superoxide produced will activate Src, PYK2 and JAK2 
to promote RhoGEF activation [174, 295], as described above. Stretch induces integrin engagement 
with the extracellular matrix, FAK auto-phosphorylation and subsequent RhoGEF phosphorylation 
[270]. This ‘outside-in’ FAK activation is also associated with activation of NOX4/Poldip2 [229]. One 
study shows that NOX4/Poldip2-depedent H2O2 production induced by integrin engagement results in 
direct cysteine oxidation of filamentous actin and this promotes subsequent maturation of focal 
attachments [49]. Another study has shown that NOX4 derived ROS oxidise integrin 71 and that 
this induces extracellular matrix binding [388] and potentially additional activation of FAK, suggesting 
a two-way relationship between integrin engagement and NOX4 activation which may strengthen the 
transmission of contractile force [389]. This response to stretch is of particular importance to the role 
of NOX in myogenic contraction (section 4.6). In line with the importance of RhoA/ROCK signalling in 
GPCR-induced VSM contraction and the role of NOX in activating ROCK, GPCR-induced 
translocation/activation of RhoGEFs/RhoA and/or MYPT1/MLC20 phosphorylation in rat afferent 
arterioles, and mesenteric, tail and pulmonary arteries, are inhibited by non-specific antioxidants, 
SOD-mimetics or NOX blockers [106, 114, 133, 135, 174].   
 
Unlike superoxide, some reports suggest that exogenous H2O2 induces contraction in a number of 
vascular beds that is insensitive to ROCK inhibition and is not associated with RhoA or ROCK 
translocation or phosphorylation of MYPT1, and is even independent of MLC20 phosphorylation [311, 
326, 343, 346, 347]. Indeed H2O2 actually suppresses basal MLC20 phosphorylation at the main MLCK 
target site (Ser19) [326, 343]. Instead, in permeabilised, Ca2+clamped tissues H2O2 causes a contraction 
that is sensitive to inhibition of PKC [326, 343]. In parallel to ROCK-dependent MLCP inhibition via 
MYPT1, PKC, which is itself directly ROS sensitive [176, 321, 322], also inhibits MLCP through 
phosphorylation of the inhibitory protein, C-kinase potentiated protein phosphatase-1 Inhibitor-17 
(CPI-17) [135, 382, 390]. In addition, there are two further routes through which ROS, with the 
involvement of PKC, could influence contractile force, and both involve actin polymerisation. Firstly, 
there is heat-shock protein-27 (HSP27) a chaperone which prevents actin polymerisation, unless 
phosphorylated and inhibited by p38 MAP-kinase via MAP-Kinase activated protein kinase [315]. 
Secondly, there is caldesmon, which inhibits actin-myosin interaction unless it is phosphorylated and 
inhibited by ERK MAP-kinase [391]. ERK and p38 MAP-kinases are both indirectly activated by ROS via 
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upstream PKC-mediated MEK phosphorylation [156, 194, 392]. MEK is also activated via oxidative 
inhibition of upstream inhibitory PTPs [268], oxidative activation of Ras [393] or Src-dependent RTK 
transactivation and recruitment of GRB2, Ras and Raf. In line with these signalling pathways being pro-
contractile in VSM, constrictions induced by exogenous H2O2 or NOX-dependent GPCR agonists or 
stretch are inhibited by blockers of either p38 or ERK MAP-kinases [103, 194, 283, 341, 352-354, 394, 
395]. ROS-dependent, Ca2+-independent contractile signalling pathways are summarised in Figure 5. 
 
4.5. Role of NOX in GPCR-induced contraction. Having established the pro-contractile effects of ROS 
in VSM and the signalling pathways involved, this review now addresses the relevance of NOX-derived 
ROS to physiological vasoconstrictor stimuli, starting with GPCR agonists. These include agents 
involved in the control of mean arterial blood pressure and central control of regional blood flow (Ang 
II, noradrenaline) or local control of blood flow (ET-1, adenosine, 5-HT, prostaglandins, sphingolipids 
etc), all of which are known to activate NOX and stimulate ROS production (Table 1). Complementary 
to this, a variety of studies in isolated arteries from various vascular beds have utilised non-selective 
antioxidants, pharmacological manipulation of NOX and antioxidant enzymes, to examine the role of 
NOX in VSM contraction (Table 2). For example, Ang II in isolated aorta, mesenteric, cerebral and 
pulmonary arteries and renal afferent arterioles [89, 99, 104, 105, 133, 137, 325, 335, 377, 378], 
catecholamines in aorta, tail artery and renal arteries [131, 135, 137, 226], ET-1 in mesenteric and 
pulmonary arteries [66, 114], eicosanoids in mesenteric, coronary and pulmonary arteries [66, 140, 
146, 148, 174], adenosine in aorta [116] and 5-HT in pulmonary artery [138], all cause constriction in 
part via NOX and ROS. A couple of these studies have also examined the role of NOX-derived ROS in 
renal haemodynamics in vivo. Infusion of an antioxidant or NOX inhibitor enhances baseline renal 
blood flow [137]. Such infusion also reverses the inhibition of renal blood flow by Ang II or 
noradrenaline and antagonises the concomitant increase in renal vascular resistance [133, 137]. 
Through the use of knockout mice or specific inhibitors, these responses have been attributed to NOX1 
or NOX2 (p47phox-/-)[104], NOX1 alone (NOX1-/-) [89, 138, 148], NOX2 alone (gp91ds-tat, NOX2-/-) [133, 
140], or Poldip2/NOX4 (Poldip2+/-) [226]. The role of NOX in Ang II induced vasoconstriction is of 
particular importance to the study of NOX involvement in hypertension (section 6). 
 
4.6. Role of NOX in myogenic, pressure/stretch-induced contraction. In a number of vascular beds, 
arterioles constrict in response to increased perfusion pressure (myogenic tone) in order to maintain 
adequate organ blood flow despite changes in MAP and prevent tissue damage through excessive 
flow. This is important in the cerebral [325, 396] and renal circulations [397], but has been studied 
most extensively in the renal afferent arteriole, where NOX-derived ROS play an important role. In the 
perfused pressurised afferent arteriole, endogenous superoxide production is increased by raising 
perfusion pressure [104, 230, 327, 334] (Table 1) and the response is suppressed in p47phox-/- mice, 
suggesting the involvement of NOX1 or NOX2 [104, 230] or in Poldip2+/- mice suggesting the additional 
involvement of NOX4 [230] (Table 2). There is limited evidence that stretch activates NOX in other 
vascular beds. Myogenic tone is of marginal importance in coronary arteries, and pulmonary arteries 
do not generate force in response to stretch alone, but passive stretch does influence force generated 
in response to other stimuli. For example, depolarisation induced contraction in bovine pulmonary 
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and coronary arteries is enhanced by previous application of supra-physiological stretch and this 
enhancement appears to be dependent on NOX-derived ROS [194, 353].   
 
Exactly how NOX1 or NOX2 are activated by stretch in VSM is unknown, but it is reasonable to 
speculate that a key step is the integrin-mediated activation of Src and FAK following stretch-induced 
binding of integrins with the extracellular matrix, the so-called ‘outside-in’ activation pathway, 
perhaps via interaction with transmembrane PTPs [398]. This may also involve subsequent activation 
of PKC. Indeed, one study in femoral artery suggests that stretch-induced ROS production requires 
PKC-dependent phosphorylation of p47phox [162]. Like GPCR-induced responses, myogenic contraction 
involves both Ca2+ influx (primarily via LVGCC) and RhoA/Rho-kinase mediated Ca2+ sensitization [325, 
327, 355, 399] and NOX-derived ROS will contribute to these, perhaps via stretch-induced Src- and 
PKC-dependent LVGCC phosphorylation [363-365] or RhoGEF phosphorylation [145, 313, 314]. An 
important role for NOX1 or NOX2-derived superoxide in myogenic contraction is suggested by the 
inhibitory effects of antioxidants, pharmacological NOX inhibitors and p47phox knockout in isolated 
perfused renal afferent arterioles [99, 104, 230, 325, 334]. A pathway for NOX4 activation by integrin 
engagement which may contribute to myogenic tone can be inferred from the known association 
between Poldip2/NOX4, integrins, FAK and the actin cytoskeleton, and its role in integrin-induced VSM 
focal adhesion turnover [47, 49, 107, 228, 229] (Figure 5, and see also section 6.3 on the role of NOX 
in VSM migration). However, contrary to this and contrary to the proposed role for NOX4 in Ca2+-
independent contraction via actin polymerisation, NOX4-derived H2O2 appears to be antagonistic of 
NOX1- or NOX2-derived superoxide and inhibitory of myogenic tone, rather than contributing to it. 
Note that afferent arteriole myogenic tone is also inhibited by over-expressing SOD and suppressed 
with PEG-SOD or enhanced in SOD-/- mice, strongly suggesting that superoxide, not H2O2, is the specific 
ROS mediating this response [99, 230, 334]. Conversely, inhibiting NOX4-derived H2O2 with PEG-
catalase or in Poldip2+/- mice has the opposite effect, enhancing myogenic tone, indicating a pro-
relaxant effect of H2O2 [230, 327]. Consistent with this, exogenous superoxide enhances myogenic 
tone in cerebral arteries and renal afferent arterioles [325, 327] while exogenous H2O2 has a mixed 
dose-dependent effect on myogenic tone in renal afferent arterioles, enhancing the response at low 
concentrations but causing relaxation at higher concentrations [334]. The pro-relaxant properties of 
ROS, and H2O2 in particular, are discussed further in the next section. 
 
5. Role of NOX in VSM relaxation.  
Exogenous superoxide, as generated extracellularly by xanthine/xanthine oxidase or intracellularly by 
LY83583 or menadione, relaxes rat aorta and mesenteric and femoral arteries pre-stimulated with 
vasoconstrictor GPCR agonists [311, 333, 351] and suppresses rat cerebral myogenic auto-regulation 
in vivo [396]. Superoxide may do this independently of its dismutation to H2O2 [311], but exogenous 
H2O2 also clearly causes relaxation in a range of systemic vascular preparations pre-stimulated with a 
range of vasoconstrictor GPCR agonists [336, 350, 354, 400-407] or pressure-induced myogenic tone 
[327, 334, 354, 408-411] and increases canine coronary blood flow in vivo [336] (Table 3). Thus, 
perhaps paradoxically, as well as mediating vasoconstriction, endogenous ROS also mediate 
vasodilation, often in the same vascular beds. This section discusses the evidence for a vasodilatory 
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action of NOX-derived ROS in response to normal physiological vasodilatory stimuli, focussing on the 
regulation of its production, its role in modulating endothelial function and its target pro-relaxant 
effector pathways in the smooth muscle.  
 
5.1. Activation of Endothelial NOX. Physiological stimuli that trigger VSM relaxation and increase 
blood flow include vasodilatory GPCR agonists such as acetylcholine (from parasympathetic efferent 
nerves), histamine and bradykinin (local inflammatory mediators) and others, as well as flow/shear-
stress. A response to shear-stress is important in some vascular beds for accommodating increased 
flow in circumstances where cardiac output and MAP are increased, such as muscle during exercise.  
Conversely, in tissues where relatively constant flow is desirable such as brain and kidney, flow-
induced dilation balances and is balanced by pressure-induced myogenic contraction [230, 334, 412]. 
GPCR-induced and flow-induced relaxation are both endothelium-dependent and not wholly 
dependent on eNOS, therefore the ROS contributing to this relaxation are likely to be endothelial in 
origin and may act in parallel with or even influence eNOS and EDHF. As in VSM, NOX isoforms 1, 2, 4 
and 5 are all expressed in the vascular endothelium [53, 54, 215, 234, 413-415] and are likely sources 
of the ROS contributing to or influencing these relaxation responses. Indeed, acetylcholine, histamine, 
bradykinin and flow all induce NOX-derived ROS production in vascular tissues and cultured 
endothelial cells [237, 402, 405, 408, 414, 416-418, 418-421] (Table 1). Vascular relaxation responses 
in isolated arteries and cerebral blood flow are improved by non-selective NOX inhibitors [421, 422], 
and several studies have examined the role of specific endothelial NOX isoforms in endothelium-
dependent relaxation (Table 2). So far, the only unambiguous evidence for a pro-relaxant isoform is 
for NOX4. Femoral artery relaxation responses are suppressed in NOX4 knockout [52] while coronary 
perfusion pressure is depressed by over-expression of NOX4 [215]. Conversely, deletion of NOX1 
appears to improve endothelium-dependent relaxation in isolated aorta or pressurised mesenteric 
arteries [423, 424] while expression of NOX5 in mouse vasculature appears to suppress it [66]. For 
NOX2, there is conflicting evidence. Some studies using selective inhibition of NOX2 or NOX2 knockout 
suggest that NOX2-derived superoxide antagonises endothelium-dependent relaxation [418, 425, 
425], while other suggest that it supports endothelium-dependent relaxation in response to both flow 
and acetylcholine [418]. As discussed below, these differences may relate to the different pathways 
through which the four NOX isoforms respond to stimuli acting on the endothelium and the nature of 
their effects within the endothelium, but perhaps most significantly, the fact that NOX4 produces 
H2O2, not superoxide.  
 
Activation of NOX1, NOX2 and NOX5 isoforms by GPCR agonists in endothelium is essentially the same 
as in VSM and has already been discussed, while the exact mechanism of NOX4 activation by GPCR in 
endothelium remains unclear (section 2). NOX activation by laminar flow/ shear-stress on the other 
hand is specific to the endothelium because only the endothelium is in direct contact with flowing 
blood. Endothelial cells possess a mechanical flow sensor or ‘mechanosome’, a protein complex 
composed of platelet-endothelial cell adhesion molecule-1 (PECAM-1) and the adapter protein VE-
cadherin, associated with caveolin in caveolae. In response to changes in flow, this complex 
transactivates the type-2 VEGFR which then acts as a platform for the activation of PI3K [426], PKC- 
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[427], Src [428] and Rac1 [429], all of which contribute to the assembly and activation of NOX1 and 
NOX2 (see Figure 1 for more specific details). Secondly, VEGFR activation also triggers closure of KATP 
channels, similarly associated with caveolae [430, 431]. It is believed that the resultant endothelial 
depolarisation opens T-type Ca2+ channels, thus raising endothelial [Ca2+]i [432, 433]. This initial 
increase in [Ca2+]i, as well as having downstream actions, may activate PKC- or -, further 
contributing to NOX1/2 activation. It may also directly activate NOX5, although this has not been 
demonstrated experimentally. In the endothelium, caveolin-1 appears to constitutively suppress 
NOX1 and NOX2 activity in the short term and suppress their expression in the long term [48, 234, 
430, 431] and it is likely that HSP90 relieves this suppression by displacing caveolin-1 from the oxidase 
catalytic subunit [234], in a manner similar to that previously described for the activation of eNOS 
[434]. However, it should be noted that several earlier publications on the relationship between NOX 
and caveolin (not cited here) have since been retracted, so later studies should perhaps be interpreted 
with caution. NOX4 is also activated by sustained laminar shear-stress in endothelium, possibly 
explaining the high baseline levels of NOX4-derived endothelial H2O2 in vivo [291]. However, it is 
unclear how laminar shear-stress activates NOX4 since it is not located in caveolae [23] and the 
activation mechanism must differ from that described for VSM because integrins are not expressed 
on the apical surface of endothelium. Once activated, endothelial NOX generates H2O2 (NOX4) or 
superoxide (NOX1, 2 and 5) within the cell, where it contributes to the regulation of vascular tone 
through three main pathways: interaction with eNOS to regulate NO∙ production, both positively 
(H2O2) and negatively (superoxide), opening of endothelial K+ channels as part of an endothelium-
derived hyperpolarisation response, and diffusion (H2O2 only) to the VSM to cause relaxation directly, 
primarily via opening of VSM K+ channels. 
 
5.2. Cross-talk between NOX and eNOS in the endothelium. A key mediator of VSM relaxation is 
endothelium-derived NO∙, produced by eNOS through the transfer of an electron from NADPH to L-
arginine in the presence of tetrahydrobiopterin (BH4) [435]. The initial trigger for eNOS dimerization 
and activation is usually an increase in [Ca2+]i, either via sarcoplasmic reticulum Ca2+ release in 
response to GPCR agonist binding (eg acetylcholine, bradykinin and adenosine), or Ca2+ influx triggered 
by laminar shear-stress, as described above. NO∙ diffuses to the smooth muscle to cause relaxation, 
primarily via the activation of guanylate cyclase, production of cGMP and activation of protein kinase 
G (PKG), resulting in opening of K+ channels. Classically, endothelial or smooth muscle derived 
superoxide is considered a major opponent of NO∙ mediated relaxation because it will chemically react 
with NO∙, generating peroxynitrite (ONOO-) which is a relatively weak vasodilator [362, 436]. This is 
supported by the fact that applying or over-expressing SOD supports NO∙ mediated relaxation, while 
knocking out SOD has the opposite effect [99, 437]. Also, superoxide has the potential to trigger 
uncoupling of eNOS by oxidising BH4, thus forcing eNOS to make more superoxide instead of NO∙ [413, 
435]. On the other hand, endogenous SOD normally dismutates much of the endothelial superoxide 
into H2O2, which is pro-relaxant [402, 404, 410, 438], and NO∙ may indirectly support H2O2 production 
over that of superoxide through selective inhibitory S-nitrosylation of p47phox (NOX1, 2) and of NOX5 
[439, 440], but leaving NOX4-derived H2O2 unaffected [52, 440]. There is also evidence that 
endothelial ROS more directly promote eNOS activity and NO∙ production, with either NOX2-derived 
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superoxide [414, 418, 420] or NOX4-derived H2O2 [209, 291, 441], activating several protein kinases, 
including  CAMK-II, p38 MAPK and FAK, either sequentially or in parallel, resulting in eNOS 
phosphorylation and further enhanced NO∙ production [209, 291, 442]. Interestingly, it is also 
apparent that sustained periods of physiological laminar pulsatile shear-stress also suppress 
gp91phox/NOX2 expression, thus reducing basal superoxide production [414, 443]. It also upregulates 
eNOS expression [444], while at the same time it promotes NO∙ dependent down-regulation of NOX2 
expression [420].  
 
5.3. Role of NOX-derived ROS in endothelial hyperpolarisation. The second pathway through which 
ROS can promote endothelium-dependent relaxation from within the endothelium is by opening the 
intermediate and small conductance Ca2+-activated K+ channels (IKCa/SKCa) on the endothelium to 
trigger hyperpolarisation [405, 408], which then spreads to the VSM via myo-endothelial gap junctions 
[406, 445] or by the effluxed K+ diffusing to the VSM and activating VSM inward rectifier K+ channel 
(KIR) and Na+/K+ATPase, which then hyperpolarises the VSM [446, 447]. There is little evidence that 
IKCa or SKCa are directly ROS-sensitive, but they are activated by an increase in endothelial [Ca2+]i which 
can be induced by H2O2. Endothelial H2O2 may elevate [Ca2+]i by promoting Ca2+ release from the 
sarcoplasmic reticulum or by triggering endothelial Ca2+ influx, and there is evidence for both. As in 
VSM, endothelial Ca2+ release occurs through a combination of IP3R and RyR efflux pathways [448, 
449] and, also as in VSM, these may be enhanced by H2O2 [225, 450]. This idea is supported by a study 
in isolated rabbit iliac artery, where exogenous H2O2 enhances the release of endothelial sarcoplasmic 
reticulum Ca2+ and relaxation triggered by pharmacological SERCA inhibition, and the enhanced 
relaxation is suppressed by blockers of IKCa / SKCa and myo-endothelial gap junctions [406]. 
Alternatively, the endothelial transient receptor potential ankyrin-1 (TRPA1) is also directly ROS-
sensitive [451, 452]. TRPA1 has a large conductance and may itself facilitate sufficient endothelial Ca2+ 
influx to activate co-localised SKCa and IKCa on the endothelial basolateral surface [453-456]. One 
additional study provides evidence supporting a role for NOX-derived H2O2 in endothelial 
hyperpolarisation. Here, enhanced ACh-induced relaxation induced by endothelium-selective over-
expression of NOX4 in isolated aorta was normalised by catalase, KCl and blockers of SKCa and IKCa, 
suggesting that the extra H2O2 generated was acting within the endothelium to promote endothelial 
hyper-polarisation [215]. Therefore, H2O2 may play an accessory role in endothelium-dependent 
relaxation as a promotor of endothelial-VSM electrical coupling. 
 
5.4. NOX-derived H2O2 as a diffusible hyperpolarising factor. EDHF was originally defined to describe 
an unknown factor or factors that may be responsible for the component of endothelium-dependent 
hyperpolarising vasodilation not due to NO∙ or prostacyclin [457, 458]. We now know that EDHF 
probably comprises no single factor but a range of diffusible factors or processes coupling endothelial 
hyperpolarisation to smooth muscle hyperpolarisation and relaxation [446, 459]. In addition to 
contributing to endothelial hyperpolarisation and electrical coupling between endothelium as 
described above, H2O2 may itself be one of these proposed factors that diffuses to the VSM and causes 
hyperpolarisation [410]. Flow/shear-stress and vasodilatory GPCR agonists such as acetylcholine, 
bradykinin, histamine, substance P and adenosine induce hyperpolarisation and dilation of a wide 
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range of isolated resistance-sized systemic arteries/arterioles from various mammalian species that is 
suppressed when SOD is inhibited or knocked out or when catalase is applied, and is restored by 
applying SOD or SOD mimetics [52, 102, 117, 139, 215, 400-402, 404-406, 408, 410, 411, 418, 421, 
425, 437, 438, 460-463]. Thus, it is presumably H2O2 not superoxide, that plays the major role in 
relaxation responses to physiological vasodilator stimuli, even though exogenous superoxide is also 
capable of relaxing VSM. This may be partly because superoxide scavenges NO∙ but H2O2 does not, 
and partly because H2O2 is more freely diffusible and membrane permeable than superoxide. In many 
of the studies implicating H2O2 as an EDHF, the principle source of endothelial H2O2 is not clearly 
defined, although a role for NOX can often be inferred. Two studies have directly linked NOX to EDHF, 
suggesting that either inhibition of NOX2 or knockout of NOX4 will remove the PEG-catalase 
inhibitable component of adenosine-induced relaxation of isolated rat cerebral arterioles [117] or of 
flow-induced femoral dilation in vivo [52]. One alternative source is uncoupled eNOS [402, 461].  
 
5.5. Pro-relaxant targets for ROS in VSM. In arteries pre-stimulated with constrictor GPCR agonist or 
myogenic tone, the EDHF component of relaxation induced by vasodilatory GPCR agonists or flow after 
blockade of eNOS or prostacyclin production, is inhibited by a depolarising KCl solution to remove the 
influence of K+ channels on VSM membrane potential [402, 405, 411], suggesting that EDHF ultimately 
relaxes the VSM by opening K+ channels, triggering hyperpolarisation, closing LVGCC and lowering 
[Ca2+]i. In similarly pre-constricted vessels, the relaxation induced by either H2O2 or superoxide is also 
inhibited, or even turned into a contractile response by KCl, supporting the hypothesis that H2O2 is an 
EDHF [148, 336, 341, 342, 350-352, 354, 402, 405, 407, 408, 411].  
 
VSM express a range of K+ channels including, most notably, a number of different KV channels and 
the large conductance Ca2+ activated K+ channel (BKCa). However, there appears to be conflicting 
evidence over which of these two types of channel are the most important in mediating VSM 
hyperpolarisation responses to physiological vasodilatory stimuli. Certainly there is conflicting 
evidence over which is important in mediating the hyperpolarising and pro-relaxant effects of 
exogenous H2O2 or superoxide. Some studies show that superoxide or H2O2-induced relaxations of 
GPCR-mediated or myogenic contractions in coronary and mesenteric arteries or renal afferent 
arterioles are prevented by selective pharmacological inhibition of KV channels (eg. 4-aminopyridine, 
4-AP, linopirdine), but not of BKCa channels (eg. TEA, iberiotoxin) [327, 336, 350, 351, 366, 407, 464], 
or that H2O2 enhances coronary blood flow in dogs in vivo and this is blocked by 4-AP [336]. In line 
with this, at the single cell or single channel level, a few studies show that exogenous superoxide 
(10µM LY83583) and somewhat high concentrations of H2O2 (1-10mM) both activate 4-AP sensitive KV 
currents in isolated coronary and mesenteric VSMCs [350, 351, 366, 407]. KV channels expressed in 
VSM may be directly ROS sensitive since the current enhancement by H2O2 in coronary arterial VSMCs 
is prevented by thiol alkylation [366] and KV2.1 is modified by direct S-glutathionylation (oxidised 
glutathione) in mesenteric artery VSMCs to increase its voltage sensitivity [407], or it may be indirect 




Curiously, despite all the evidence described above that KV channels are preferentially activated by 
ROS and contribute to ROS mediated relaxation, when examining hyperpolarisation and VSM 
relaxation induced by physiological vasodilatory stimuli acting via endogenous H2O2, the majority of 
evidence points towards BKCa as the likeliest target channel because acetylcholine and flow both 
induced relaxation in coronary or mesenteric arteries that is suppressed by inhibitors of BKCa channels 
(TEA, TBA, iberiotoxin, paxilline) [402, 403, 410, 411, 460, 462, 462]. This is also supported by 
additional studies showing that exogenous superoxide (X/XO) and physiological concentrations of 
H2O2 (1-100µM), as well as perfusate from mesenteric arteries containing endogeous H2O2, activate 
single channel BKCa currents in canine cerebral artery or human coronary artery VSMCs [396, 403, 410, 
460]. Unlike for KV channels, there is limited evidence for direct oxidative activation of BKCa. Although 
the human BKCa channel reportedly possesses a disulphide switch in non-vascular cells [465], there is 
no evidence to support its direct oxidative modification in vascular cells, indeed physiological 
concentrations of exogenous H2O2 (<100 µM) only effectively activates BKCa in cell-attached patch-
clamp configuration, indicating the requirement of intracellular signalling [403, 410]. It is more likely 
that it requires oxidative activation of kinases that phosphorylate and open these channels, 
particularly PKGI either directly (independently of cGMP) [327, 400, 401, 403, 466], or via oxidative 
activation of guanylate cyclase which generates cGMP, the main activator of PKG [467, 468]. In 
addition to opening K+ channels, there is some evidence that under certain circumstances, ROS and/or 
NO∙ may promote relaxation by inhibiting L-type Ca2+ channels through direct thiol sulfonylation or S-
nitrosylation  [359-362]. However, it is unclear how this mechanism can operate and be regulated 
alongside the better characterised indirect opening of L-type Ca2+ channels by ROS-dependent 
phosphorylation or membrane depolarisation (section 4.2). Finally, [Ca2+]i may be lowered to promote 
relaxation through glutathionylation and activation of VSM SERCA [380]. All of the interactions 
between endothelial superoxide, H2O2 and NO∙, their contribution to EDHF and VSM relaxation and 
the effector pathways are summarised in Figure 6.  
 
A big question remains though: how ROS can have opposing effects, contraction and relaxation, in the 
same tissue or even the same cell within that tissue, and how the final net response is obtained. This 
presumably relates to the relative sensitivity of the various ROS effector pathways to ROS and 
therefore the concentration of ROS applied, but also to the relative expression levels of components 
of those pro-contractile and pro-relaxant pathways and their possible co-localisation with NOX in the 
endothelium and VSM. Differential effects of superoxide vs. H2O2 within the cell may also be 
important, and therefore the relative activities and distributions of SOD and catalase. Clearly, the 
nature of the pre-constriction influences the outcome, not only by altering the balance between 
LVGCC and K+ channel activity but also the contributions of VSM sarcoplasmic reticulum Ca2+ release 
and Ca2+ sensitization pathways, both of which are also ROS sensitive but minimally influenced by 
membrane potential or NO∙.  
 
6. Role of NOX-derived ROS in hypertension. 
Hypertension is a persistent increase in baseline MAP, which if uncorrected will result in cardiac 
remodelling and ultimate heart failure. There are various causes, including over-activation of the 
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renin-angiotensin-aldosterone system and sympathetic nervous system, various genetic factors and 
environmental/life-style factors, such as a high salt diet, excess body weight and smoking [469-472]. 
Regardless of cause, disease progression involves several underlying mechanisms, including 
inflammation, smooth muscle hyper-contractility coupled with impaired endothelial function, smooth 
muscle proliferation and migration. A common feature of all these processes and the resultant 
hypertension is oxidative stress, as indicated by elevated levels of malondealdehyde and F2 
isoprostanes, resulting from excessive ROS production, reduced NO∙ availability and impaired 
antioxidant defences [113, 415, 470, 472-478]. A clear causative link between oxidative stress and 
hypertension remains a matter of debate, especially in humans where there also remains uncertainty 
over the therapeutic benefit of antioxidants [469, 470, 472, 474, 476, 477, 479-482]. However, such a 
link is well characterised in multiple animal models of hypertension, such as the spontaneously 
hypertensive rat (SHR), renovascular hypertension, deoxycorticosterone acetate (DOCA) salt rat, 
obese rat and the Ang II-infused rat or mouse. These have been used to examine the mechanisms 
underlying oxidative stress and its role in the pathophysiology of hypertension. Throughout earlier 
sections of this review are detailed the various cellular target signalling pathways for NOX-derived ROS 
that contribute to the normal functioning of the vasculature, both pro-contractile and pro-relaxant. In 
this section will be outlined evidence for how these pathways are altered in oxidative stress to 
promote a hyper-contractile state, how excess ROS induce vascular remodelling through stimulation 
of VSM growth, proliferation and migration and fibrosis, and briefly, the role of NOX/ROS in vascular 
inflammation.   
 
6.1. Expression of NOX isoforms/subunits in hypertension. Individually, NOX isoforms may contribute 
to VSM hyper-contractility or remodelling in response to hypertensive stimuli through altered activity, 
expression or both [80]. NOX1 and 2 are both upregulated in SHR compared to Wistar-Kyoto control 
(WKY) rats [415, 483-485]. The regulation of subunit NOX expression by long-term treatment of 
vascular cells/tissues with mitogenic GPCR agonists and growth factors/cytokines has been reviewed 
extensively elsewhere [23, 474, 486]. Examples from rat or mouse models include expression of NOX1, 
NOX2, p22phox, p47phox and p67phox in VSM being enhanced by Ang II infusion [26, 40, 45, 82, 423, 423, 
473, 483, 487-491], NOX1 being enhanced by PDGF [40], NOX1 by stretch [492] and NOXA1 by TNF- 
[126]. There is some disagreement over whether NOX4 is also upregulated in SHR, with several studies 
saying it is [70, 483, 485, 493, 494] and some saying it is not [415]. Regulation of NOX4 expression by 
mitogenic and inflammatory stimuli in hypertension is also contentious. Several reports suggest NOX4 
is upregulated by GPCR agonists and inflammatory mediators in VSM [47, 120, 263, 423, 489, 494, 
495] while a few others suggest it is down-regulated by Ang II and PDGF [40, 45, 473]. However, a 
recent study suggests that, either in SHR or during Ang II infusion, expression of NOX4 in VSM is 
enhanced, and this occurs by the suppression of B-cell lymphoma 6 (BCL6) [494]. BCL6 itself normally 
suppresses NOX4 expression, reduces oxidative stress and impairs aortic wall thickening [494]. NOX5 
expression is enhanced by Ang II, ET-1 and inflammatory mediators such as TNF- in human VSMCs in 
vitro [57, 496]. It is not clear whether native NOX5 expression is altered in VSM in hypertensive 
humans but it is upregulated in renal proximal tubule cells [497]. There is limited evidence that NOX 
polymorphisms are associated with hypertension risk in humans [470]. p22phox polymorphisms show 
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either a protective association or an increased risk [498] and seven identified polymorphisms in NOX5 
result in reduced or absent enzyme activity [499]. See Figure 7 for a summary of all the factors 
influencing NOX expression in hypertension. 
 
6.2. Impaired NO∙-dependent relaxation and enhanced contractility. In SHR, amplitude of 
phenylephrine-induced contraction in isolated aorta is enhanced while acetylcholine induced 
relaxation is impaired compared to WKY controls and these differences are normalised by antioxidants 
and NOX inhibitors (tiron, tempol, apocynin, VAS2870) or catalase [415, 423, 425, 489]. If there is an 
imbalance between ROS production and antioxidant defences, then excess superoxide in the 
vasculature will have two immediate effects. Firstly, it will react with NO∙ in an uncontrolled way, 
resulting in the production of excess ONOO- and secondly it will trigger uncoupling of eNOS through 
oxidation of BH4, forcing eNOS to make superoxide instead of NO∙. Excessive ROS, particularly hydroxyl 
radical, may also directly inactivate guanylate cyclase [484, 500]. Hypertensive agents such as Ang II 
and TXA2 promote eNOS uncoupling [5, 6, 66, 414, 422, 435, 501]. The degree to which this eNOS 
uncoupling impairs agonist-induced relaxation will also depend on how much of the superoxide 
produced is dismutated to H2O2 in the endothelium, and this will depend on the expression and 
location of SOD, which may or may not be down-regulated [99, 422]. The net effect will be impaired 
NO∙ mediated relaxation via K+ channel closure and VSM depolarisation [425]. However, these 
pathways do not solely account for the hyper-contractile phenotype. Hypertension is also associated 
with a dysregulation of intracellular Ca2+ in the VSM [70, 502-504] and this is influenced by VSM 
oxidant stress [13, 70, 376]. There is evidence for both enhanced Ca2+ influx through LVGCC [503-507] 
and altered sarcoplasmic reticulum Ca2+ handling [506, 508, 509], but it perhaps remains to be clarified 
which of all the various ROS-dependent Ca2+ signalling pathways described in this review are 
predominantly upregulated in hypertension. For example, one study shows in mesenteric arteries 
from SHR, that H2O2 induces a greater LVGCC-mediated Ca2+ influx than in WKY control rats [348], 
while others suggests that one consequence of oxidative stress on [Ca2+]i is that excessive cytosolic 
superoxide results in irreversible inhibition of smooth muscle SERCA, preventing the normal pro-
relaxant, NO∙-mediated S-glutathionylation of the ATPase [380] (section 5.5). 
 
Hypertension is also associated with an increased activity of the RhoA/Rho-kinase signalling pathway 
and this also mediates both enhanced VSM contractile responses and VSM proliferation/migration 
[510-514]. As discussed earlier in this review, RhoA is both directly [385, 386] and indirectly ROS 
sensitive, so this enhanced activity could be NOX-dependent, perhaps via an upstream ROS-sensitive 
tyrosine kinase. For example, an Ang II-induced increase in MAP and aortic remodelling is suppressed 
in smooth muscle JAK2 knockout mice and part of the effect is ROS-dependent [192]. In carotid artery 
from SHR, enhanced agonist-induced contraction is inhibited by antioxidants and NOX inhibition while 
exogenous H2O2 causes a greater degree of Rho-kinase-dependent contraction than in WKY rats [515]. 
Antioxidants such as the putative SOD mimetic tempol and vitamins C and E lower blood pressure in 
various rodent models of hypertension [133, 516-520]. This effect is also accompanied by corrected 
endothelial dysfunction, particularly improved NO∙ activity and reduced agonist evoked ROS 
production, and normalised blood vessel contractility and vascular resistance [519]. SOD itself has a 
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similar restorative effect on endothelium-dependent relaxation [102, 425] and blood pressure [488], 
while knocking out SOD1 enhances the transient phase of Ang II-induced hypertension in mice, 
suggesting a specific role for superoxide in mediating the initial pressor response [99]. Taken as a 
whole, these data suggest that a key feature of hypertension is indeed a shift in the balance between 
pro-contractile and pro-relaxant effects of ROS contributing towards a hyper-contractile phenotype 
(Figure 7). 
 
6.3. Vascular remodelling in hypertension. Vascular remodelling, resulting in thickening of the 
smooth muscle, narrowing of the lumen and increased vessel stiffness, is a key feature of 
hypertension, either as a primary cause of elevated MAP or as a secondary response to prolonged 
periods of elevated perfusion pressure. Either way, ROS are essential components of the signalling 
pathways involved in this process (Figures 7 & 8). For VSM proliferation, various stimuli and proximal 
ROS-sensitive kinases, including Src, CAMK-II and PKC, converge on ERK MAP-kinase via growth-factor 
transactivation and Ras [521], or via phosphorylation of Raf and/or MEK [522, 523] or via PYK2/JAK2 
[524]. Once phosphorylated, ERK translocates to the nucleus to induce gene expression and cell 
division and ROCK may supporting this translocation [525]. In addition, there is the JAK/STAT pathway, 
a common route for inflammatory responses and gene expression. JAK2 is principally induced by 
cytokine receptor activation, but it is also activated by GPCRs to phosphorylate signal transducer and 
activator of transcription (STAT), triggering its translocation to the nucleus to regulate gene 
expression. JAK2 also stimulates ERK phosphorylation [526], possibly downstream of ROS-activated 
Src family kinases [188, 527], PKC- [170] or PYK2 [524]. PYK2 is activated by Ca2+, often in response 
to induced sarcoplasmic reticulum Ca2+ release, triggered by IP3 generated by PLC- (GPCR coupled) 
or PLC- (RTK-coupled). p38 MAP-kinase is also activated by MEK in response to various mitogenic 
GPCR or RTK stimuli via NOX-derived ROS or by TNF- via apoptosis signal-regulating kinase-1 (ASK-1) 
in VSM endosomes. The latter requires NOX1-dependent oxidative activation of ASK-1 [248, 252]. 
Finally, PI3K is a key stimulator of cell growth and cell survival, acting via AKT, mammalian target of 
rapamycin (mTOR), S6-kinase and eukaryotic translation initiation factor 4E-binding protein (4EBP) 
[528].  
 
Cell migration requires a dynamic cell polarisation involving co-ordinated cycles of actin de-
polymerisation and polymerisation at the trailing and leading edges. This is dependent on activation 
of small G-proteins RhoA, Rac and cdc42, as well as FAK, interaction with ILK and cross-talk with 
extracellular matrix [107, 529]. ROS-activated CAMK-II may facilitate VSMC migration by activating the 
matrix metalloprotease MMP9 [328, 530]. At the leading edge of the migrating cell, actin 
depolymerisation is required for the formation of new actin fibres and this is achieved through the 
ROS-dependent de-phosphorylation and activation of cofilin by the PTP slingshot-1L following NOX4-
dependent oxidation of 14-3-3 [531, 532].  Rho and Rac are often activated by migratory stimuli via 
tyrosine phosphorylation of their respective guanine nucleotide exchange factors, by Src, FAK, PYK2 
or JAK2 and once activated they collectively promote actin reorganisation [145, 189, 190, 192, 313, 
314]. Poldip2 may facilitate activation of RhoA and focal adhesions via NOX4-derived ROS activating 
associated RhoGEFs [247], perhaps via ROS-induced tyrosine phosphorylation. CAMK-II also promoted 
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migration via Rac [533]. As well as responding to inflammatory mediators [534], VSM NOX-derived 
ROS also positively influence vascular inflammation in hypertension. One study suggests that vascular 
oxidant stress is sensed by resident dendritic cells through the formation of isoketal protein adducts, 
leading to T-cell recruitment and activation and the release of cytokines that promote fibrosis and 
arterial stiffening [535]. 
 
FAK is a common point for cross-talk between GPCRs, RTKs and integrins. The ‘inside-out’ FAK 
activation pathway involves GPCR mediated NOX1 or NOX2-dependent activation of FAK, probably via 
Src [314], subsequent dissociation of ILK from clustered integrins, paxillin phosphorylation and RhoA 
activation, promoting migration through actin polymerisation and focal adhesion turnover at the 
leading edge [107, 529, 536-538]. There may then be secondary further integrin-dependent activation 
of NOX, possibly NOX4, following GPCR-induced FAK-activation, involving integrin 11 [107]. FAK 
may also promote VSM proliferation and migration in response to enhanced perfusion pressure, 
because it will be activated by ‘outside-in’ stretch-induced integrin engagement [539]. FAK is also 
coupled to NOX4/Poldip2 activation and in combination they are capable of subsequently activating 
both Src and RhoA [49, 226, 229, 296, 539-541] and acts as an alternative platform for GRB2 docking 
and Ras/Raf/MEK/ERK signalling and PI3K/AKT activation, thus promoting both proliferation and 
migration of VSMCs in response to elevated pressure [107, 529, 539, 541]. Activation of FAK by stretch 
may also be ROS-dependent considering that NOX4 is located at focal attachments and potentially 
influences integrin-dependent signalling by oxidising integrin 71 [49, 388]. FAK activation by NOX4 
at focal adhesions probably involves oxidative inhibition of FAK phosphatases LMW-PTP or SHP2 [189, 
542, 543]. Phosphorylation of Src, FAK and PYK2 are all increased in VSM of SHR [485, 544], while Ang 
II-induced ERK phosphorylation and impairment of vascular function are normalised by Src inhibition 
[101, 544].  
 
In VSMCs, exogenous H2O2 induces transactivation of EGFR, PDGFR or IGFR, GRB2/Ras/Raf assembly 
and subsequent ERK phosphorylation [103, 173, 267, 274, 309, 545] and AKT activation [309]. 
Phosphorylation of EGFR, PDGFR and IGFR are also all enhanced in VSMC of SHR [485].  Evidence 
supports a role for Src or Fyn, PKC-, PYK2 and JAK2 in mediating these effects [173, 527, 546] and Src 
auto-phosphorylation is also enhanced in VSMC of SHR [485]. Knocking out SOD has a similar effect to 
that of exogenous ROS, promoting ERK and JAK/STAT phosphorylation and proliferation [547]. In 
addition to the proliferative, hypertrophic and migratory pathways mediated by ERK, JAK/STAT, 
PI3K/AKT and FAK/RhoA another important element of VSM hypertensive remodelling is nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-B). NF-B is normally involved in 
inflammatory and cell survival responses to cellular stress such as cytokines and ROS [255, 534, 548] 
but becomes over-activated under oxidative stress, and contributes to the stimulation of VSM 
proliferation. NF-B is activated by these stimuli through the degradation of an inhibitory I-B protein 
and Src may contribute to ROS-dependent NF-B activation in VSM by phosphorylating I-B alpha 
[259, 549]. Alternatively, NF-B may be activated via p38 MAP-kinase downstream of TNF- receptor-
1 stimulation via TRAF2 and ASK-1 [252, 550]. The NF-B signalling pathway is opposed by nuclear 
factor erythroid 2-related factor 2 (Nrf2) which plays a cyto-protective role under oxidative stress by 
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inducing expression of anti-oxidant enzymes [548]. Nrf2 translocation to the nucleus is promoted by 
oxidative inhibition of KEAP-1 which degrades cytosolic Nrf2 [551].  
 
In vivo, one would expect an early key response to oxidative stress to be excessive oxidative inhibition 
of PTPs and over-stimulation of NRTKs resulting in an overall enhancement of tyrosine 
phosphorylation, which would have consequences for both contractility and VSM 
growth/proliferation and migration [21]. One recent study suggests that coupled with ER stress, 
oxidative stress may induce VSM proliferation through irreversible hyper-oxidation (sulfinic and 
sulfonic acid) of PTPs [70]. Antioxidants also suppress many of the above described signalling pathways 
and processes associated with hypertension, including NRTK phosphorylation [110, 538, 546], growth 
factor receptor transactivation [103, 121, 136, 147, 149, 194, 274], AKT activation [109, 136, 150], ERK 
phosphorylation [64, 103, 109, 110, 136, 147, 149, 156, 194, 267, 274] and VSM hypertrophy [96, 552], 
proliferation [118, 121, 187, 267, 317, 485] and migration [100, 222, 229, 267, 538], in response to a 
range of GPCR agonists, growth factors and stretch (Table 4, Figures 7 & 8). A few studies highlight the 
importance of Src in hypertension, both as an upstream regulator of NOX and as a proximal ROS-
sensitive kinase important in contraction and proliferation, by showing that oxidative stress and 
impaired cardiovascular function induced by Ang II infusion or in SHR vs. WKY rats are all improved by 
treatment with a Src inhibitor [82, 101, 485]. 
 
In animal models of hypertension, or in VSMC treated with hypertensive agents, the broad spectrum 
NOX/flavoprotein inhibitors diphenyleneiodonium (DPI) and apocynin inhibit growth-factor 
transactivation [103, 121, 136, 147, 149, 194, 316], ERK phosphorylation [64, 103, 109, 110, 121, 136, 
147, 149, 156, 194, 316], AKT activation [109, 126], proliferation [79, 80, 107, 118, 121, 126, 127], 
hypertrophy [79, 80, 96, 109, 136, 147] and migration [100, 147, 178, 222]. Apocynin also normalises 
blood pressure and vasoconstrictor responses in spontaneously hypertensive rats [553, 554], DOCA 
salt rat [555] and dopamine D2 deficient mice [556]. A more recently developed inhibitor, VAS2870 
also normalises MAP and improves acetylcholine-induced relaxation in isolated aorta [415].  While 
originally thought to be NOX-specific, DPI, apocynin and VAS2870 are considered as broad spectrum 
flavoprotein inhibitors, potentially acting on other sources of ROS or as direct antioxidants [474]. 
However, a new class of dual specific NOX inhibitors has been developed, including the NOX1/4 dual 
inhibitor GKT137831. This may be effective against hypertension induced intermittent hypoxia [557] 
and prevents hypertensive cardiac remodelling in rats [558], but does not significantly lower MAP in 
rats with hypertension induced by aortic banding [558]. GKT137831 has been deemed safe for human 
use and has progressed to clinical trials as a NOX blocker, but not yet for hypertension [474, 559]. 
Thus, the role for specific NOX isoforms in oxidative stress and its effects on the vascular wall in 
hypertension remains an avenue of active research. 
 
6.4. Effects of selective NOX inhibition or over-expression in experimental hypertension. Several 
studies have examined the effects of knockout, siRNA depletion or over-expression of NOX isoforms 
or regulatory subunits on blood pressure, associated functional abnormalities and signalling in various 
mouse or rat models of hypertension. Ang II-induced hypertension and associated increases in ROS 
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production, ERK phosphorylation, proliferation and migration are blunted in p47phox-/- mice [41, 72, 72, 
104, 166] or by p22phox siRNA or antisense [61, 157, 560], while the hypertrophic response is enhanced 
by over-expressing p22phox [552]. p22phox-/- or p22phox siRNA also reduce MAP in salt-loaded stroke-
prone SHR [561] or Ang II-induced hypertension [61, 157]. Individually, there are multiple, but often 
conflicting reports over which NOX isoforms, if any, predominate in experimental hypertension and 
associated signalling.  
 
There is disagreement over whether or not NOX1 contributes to baseline MAP in Ang II-infused mice 
[423, 490] and disagreement over whether or not the sustained phase of Ang II-induced hypertension 
is suppressed in NOX1-/- mice, with at least two saying it is [423, 490], and at least two saying it isn’t 
[277, 562]. However, one study suggests that over-expressing NOX1 specifically in the VSM enhances 
Ang II-induced hypertension [520]. The Ang II pressor response in SHR is also blunted by NOX1 siRNA 
[483]. In vitro, the impaired Ach-induced relaxation in arteries from Ang II-induced hypertensive mice 
is restored by knocking out NOX1 [423]. There is also disagreement over whether NOX1-/- suppresses 
in vivo aortic wall thickening in Ang II-induced hypertension, one showing a reduction [490] and one 
showing no effect [423]. While in vitro, Ang II-induced aortic VSMC proliferation is inhibited by NOX1 
siRNA [107], GPCR-induced transactivation of EGFR in human and mouse VSMCs is NOX1-dependent 
[125, 178], Ang II-induced aortic VSM hypertrophy is inhibited by NOX1 siRNA [89] and over-expressing 
NOX1 enhances this Ang II-induced hypertrophy [520]. There is some evidence that NOX1 is important 
in VSM migration. The increased activation of Src and FAK in kidneys of renal hypertensive mice is 
prevented by knocking out NOX1 [277], migration of human coronary artery VSMCs is NOX1-
dependent [178] and Ang II-induced aortic VSMC FAK phosphorylation, ILK activation and migration 
are all inhibited by NOX1 siRNA [107]. 
 
There is also disagreement over whether NOX2 is an essential mediator of Ang II-induced hypertension 
in mice. Several studies suggest that NOX2 knockout lowers basal MAP and the acute phase of Ang II-
induced hypertension, but not the sustained increase in MAP [277, 562, 563], while others show that 
the NOX2 inhibitor gp91ds-tat effectively suppresses Ang II-induced hypertension [98, 133]. In SHR, 
the acute Ang II-induced pressor response and myogenic contraction responses in renal afferent 
arterioles are blunted by NOX2 siRNA [483, 564]. There is also some evidence that NOX2-derived ROS 
negatively regulates endothelium-dependent relaxation. Ach-induced vasodilation is impaired in 
isolated aorta from mice with renovascular hypertension but not in NOX2-/- mice or in aorta from 
hypertensive mice treated with gp91ds-tat [425], while over-expressing endothelial NOX2 in mice 
potentiates the hypertensive effects of Ang II infusion without changing basal MAP [565]. An inhibitory 
role for NOX2 in the control of endothelium-dependent relaxation is supported by the observation 
that NO-dependent, flow-induced dilation is enhanced in humans with hereditary NOX2 deficiency 
[501]. NOX2 knockout also prevents Ang II infusion-induced aortic wall thickening [563] and NOX2 
siRNA inhibits Ang II-induced aortic VSMC proliferation in vitro [107]. 
 
There are two opposing schools of thought about the role of NOX4 in the pathophysiology of 
hypertension, perhaps because it only generates H2O2 [45, 212-215], which is generally pro-relaxant 
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in the normotensive resistance vasculature, contributing to normal endothelial function [52, 209, 215, 
291, 327, 422, 441, 444], but on the other hand its expression is upregulated in experimental 
hypertension [70, 423, 493] and by inflammatory mediators (eg TNF-) in human aortic endothelium 
[263]. One theory is that like other NOX isoforms, NOX4 makes a direct contribution to oxidative stress 
and therefore to the pathogenesis of hypertension. Two studies show that NOX4-/- or poldip2+/- 
suppress Ang II infusion-induced increases in pulse pressure or MAP in mice [226, 566] while having 
no effect on baseline MAP or cardiac remodelling [566]. Yet another study suggests that NOX4 does 
contribute to pressure overload–induced cardiac dysfunction [264]. NOX4 may be pro-contractile in 
hypertension, as suggested by a study on the hypertensive effects of chronic intermittent hypoxia in 
rats. This was associated with an increased VSM expression of RhoA and Rho-kinase which was 
normalised by the selective NOX1/4 inhibitor GKT137831 [557]. Whether this increased expression of 
RhoA and Rho-kinase equates to an enhanced Ca2+ sensitizing contractile response to vasoconstrictor 
agents via MLCP inhibition, thus opposing the normal pro-relaxant effects of NOX4-derived H2O2, 
remains to be determined. A number of studies support a role for NOX4 in hypertensive vascular 
remodelling. Inhibiting NOX1/4 normalises mesenteric VSMC proliferation in SHR [70] and NOX4 
appears to be the primary NOX isoform required for IGF-induced VSMC migration [222]. NOX4 may 
support proliferation via oxidative inhibition of SHP2 in association with PDGFR activation [258] and 
most likely supports VSMC migration in association with Poldip2, upstream of RhoA/FAK/integrin-
mediated focal adhesion turnover and stress fiber formation [107, 228, 529, 536, 537]. 
 
The other theory is that upregulation of NOX4 in hypertension may be protective, particularly in the 
endothelium. Selectively over-expressing endothelial NOX4 reduces baseline MAP and prevents the 
initial transient phase of the hypertensive response to Ang II infusion but does not influence aortic 
wall thickness [215]. NOX4 is also upregulated by pathological oscillatory shear-stress or chronic flow 
overload in endothelium, but to a greater extent than is NOX2, thus potentially shifting the balance in 
ROS species away from pro-contractile superoxide towards pro-relaxant H2O2 [215, 327, 422, 444]. 
This is supported by the possible blood pressure lowering effect of VSM PKG activation by H2O2, 
probably derived from endothelial NOX4 [400].  In contrast to the endothelium-selective knockout 
described in [215], total NOX4 knockout has no effect on baseline MAP or the Ang II-infusion induced 
increase in MAP [52], but it enhances Ang II-induced aortic hypertrophy, impairs ACh-induced 
relaxation and potentiates Ang II induced expression of inflammatory cytokines, strongly suggesting a 
protective anti-hypertensive role for NOX4-derived H2O2 [52]. It is also suggested that NOX4-derived 
H2O2 is important in maintaining VSM differentiated state by promoting expression of contractile 
proteins and inhibiting proliferation, as opposed to NOX1 which is pro-proliferative [47, 567]. NOX4 
may be anti-hypertensive and cardio-protective in part via induction of Nrf2 activity in VSM and heart 
[52, 568]. The idea of this protective NOX4/ Nrf2 axis is supported by the additional observation that 
prolonged superoxide generation by NOX1/2/5 (but not NOX4) generally results in activation of the 
pro-inflammatory and pro-proliferative transcription regulator NFKB [534, 548] (Figure 7). 
Importantly, if this protective effect of NOX4 holds true for human hypertension it may suggest 
potential detrimental side-effects or even exacerbation of symptoms with antioxidant therapy as a 




NOX5 appears to be pro-proliferative in human VSMC and endothelium, acting via activation of MAP-
kinases and JAK2 [57, 317]. However, a thorough analysis of a potential role for NOX5 in hypertension 
is hampered the fact that rodents do not possess this NOX isoform. A few recent studies have 
addressed this by examining the effects of artificially expressing human NOX5 in mice, often in specific 
cell types. Expressing NOX5 in mouse VSM enhances basal superoxide production, enhances U46619 
and ET-1 induced contraction and suppresses ACh-mediated relaxation in isolated mesenteric artery, 
but curiously does not significantly affect mesenteric artery media/lumen ratio or vessel stiffness or 
Ang II infusion-induced hypertension [66]. Thus VSM NOX5 may be involved in the control of tissue 
blood flow but not in the control of MAP. However, a number of recent studies suggest that NOX5 
may be important in human hypertension indirectly by contributing to kidney dysfunction. When 
expressed specifically in renal podocytes of mice it impairs glomerular barrier function and raises 
systolic blood pressure [569] and when expressed in mouse smooth muscle and mesangial cells it 
accelerates the development of diabetic nephropathy [570]. Thirdly, a study in human renal proximal 
tubule cells shows that in tubule cells from patients with essential hypertension NOX5 expression was 
several fold higher while NOX1, NOX2 and NOX4 were unaffected [497]. Furthermore, cells from 
hypertensive patients exhibited reduced sensitivity to dopaminergic agonists, correlating with 
impaired suppression of tubular ROS production and sodium transport, implicating renal NOX5-
derived ROS in the pathogenesis of essential hypertension [497]. 
 
Although roles for individual NOX isoforms in specific aspects of hypertension pathology, such as 
endothelial dysfunction or VSM proliferation have been suggested, there remain incompatibly 
opposing views over which specific isoforms of NOX are most important in determining the resultant 
increased MAP. Considering the general consensus over the effectiveness of antioxidants and broad 
spectrum NOX inhibitors at lowering MAP, improving endothelial function and associated remodelling 
in various animal models, and bearing in mind that the same knockout mouse often produces 
opposing results in the same model of hypertension, it is difficult to explain the discrepancies. It may 
well be that NOX4 does indeed exert both protective and pathogenic effects in hypertension, but still 
there are discrepancies. One can only speculate about subtle differences in experimental approach, 
such as doses of Ang II, duration of infusion, or methods used to measure the various functional and 
anatomical changes. Results with NOX5 are fewer but more consistent, if mice expressing human 
NOX5 are to be taken as valid models of human disease.   
 
7. NOX in the pulmonary circulation. As discussed in previous sections, in the systemic circulation as 
a whole we can make a number of generalisations about the role of NOX-derived ROS in the control 
of vascular tone: on the one hand, superoxide and H2O2 produced within the VSM contribute to 
agonist-induced contraction and myogenic tone, while on the other, ROS produced by the 
endothelium contribute to agonist or flow-induced relaxation, primarily mediated by endothelial H2O2. 
Functionally, the pulmonary circulation differs from the systemic circulation in that it must respond to 
increases in cardiac output with vasodilation, such as during exercise, to accommodate the increased 
flow. It is therefore a low resistance/low pressure system, exhibiting no flow-autoregulation and 
42 
 
minimal or absent myogenic contraction. While isolated arteries do constrict in response to 
prostaglandins, 5-HT, ET-1 and sphingolipids, the pulmonary vasculature operates largely 
independently of circulating vasoactive hormones and the autonomic nervous system, but does 
exhibit endothelium-dependent relaxation, largely mediated by NO∙, but with an additional 
contribution of EHDF, which is relatively poorly characterised in this vascular bed [571-573]. Flow-
induced dilation in the lung is believed to be achieved primarily through passive distension and 
recruitment of arterioles, although endothelium-dependent dilation may also contribute [291]. A 
perhaps unique feature of the pulmonary circulation is the fact that arteries constrict in response to 
hypoxia (hypoxic pulmonary vasoconstriction, HPV), as opposed to most systemic vessels, which dilate 
[574]. This contributes to ventilation/perfusion matching in healthy lungs, whereby regional hypoxia 
triggers constriction in that region, directing blood flow away from poorly ventilated areas to better 
ventilated areas of the lung, thus maximising blood oxygenation. This section will outline some of the 
key differences in the way pulmonary arteries respond to ROS, in comparison with systemic vessels, 
and the potential role of NOX in those differences.   
 
7.1. Differences between pulmonary and systemic arteries. Within the context of this review, one 
may ask: are there fundamental differences in the balance between pro-contractile and pro-relaxant 
effects of NOX-derived ROS in pulmonary vs. systemic arteries? In terms of relaxation, very few studies 
have examined the role of ROS in endothelial function in pulmonary arteries and these appear to 
disagree on the key points. An earlier study, comparing isolated cat cerebral and pulmonary arteries, 
suggests that acetylcholine-induced relaxation is partly suppressed by blocking endothelial SOD in 
both vessel types but is suppressed by the addition of catalase in cerebral arteries only, suggesting an 
NO∙ scavenging contractile effect of superoxide in both vessels, but that a relaxant effect of 
endothelial H2O2 is present in cerebral but absent from pulmonary [437]. In contrast, two recent 
studies have suggested a role for endothelial H2O2 in mediating an EDHF response in the pulmonary 
circulation, one showing that shear-stress activates eNOS via endothelial NOX4-derived H2O2 [291] 
and another that bradykinin-induced relaxation is suppressed by catalase, making it H2O2-dependent 
[573].  
 
As has already been noted in previous sections, the use of exogenous ROS is not a perfect tool for 
elucidating the various functions of endogenous ROS, but nevertheless, there are apparent differences 
in the way that pulmonary and systemic arteries respond to exogenously applied ROS, suggesting that 
perhaps the key differences between vascular beds lie in the effector pathways. The majority of 
studies in pulmonary arteries show that they constricts in response to exogenous H2O2, as well as to 
superoxide generated by X/XO or LY83583, whether it is applied in the presence of pre-constriction or 
not and regardless of concentration, whereas in systemic vessels, exogenous superoxide may have a 
mixed contraction/relaxation effect, depending on concentration, and H2O2 will usually relax pre-
constricted systemic vessels, regardless of concentration [291, 573]. It is also worth reiterating that 
direct constriction induced by exogenous ROS, in the absence of any pre-constriction, is common in 
pulmonary but very rare in systemic vessels, particularly resistance sized vessels (Table 3). If effector 
pathways are different or responding to ROS differently in pulmonary arteries, what may these 
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differences be? When comparing the effects of exogenous superoxide on pulmonary and mesenteric 
arteries, a key difference is that the Rho-kinase signalling pathway responds to superoxide in 
pulmonary but not mesenteric arteries. This was illustrated by LY83583 inducing contraction in -toxin 
permeabilised pulmonary but not mesenteric arteries and enhancing Rho-kinase dependent MYPT1 
phosphorylation in pulmonary but not mesenteric arteries, even though GPCR-induced contraction is 
sensitive to Rho-kinase inhibition in both pulmonary and mesenteric arteries [351]. Alternatively, 
there may be major differences in the way ion channels, particularly K+ channels, respond to ROS. 
These contractile signalling pathways and their influence by ROS in the pulmonary circulation are 
discussed further in relation to the HPV response. 
 
7.2. Role for NOX-derived ROS in HPV. In the pulmonary artery, there is almost universal agreement 
that ROS are essential mediators of HPV, but there are a number of theories about how ROS 
production or the effects of ROS on VSM function during acute hypoxia could be different in 
pulmonary arteries compared to systemic, and some of these include a role for NOX in that difference. 
Initial studies suggested NOX as the main source of ROS during HPV [575, 576] and that both basal and 
stimulated NOX-derived ROS production is several fold higher in pulmonary artery VSM compared to 
coronary artery VSM, for example [67]. Other studies showed that while HPV is preserved in gp91phox 
-/- mice [577, 578] and unaffected by NOX2 siRNA [579], hypoxia induces translocation of p47phox in 
pulmonary VSM and acute hypoxia-induced H2O2 production and HPV are partially suppressed in 
p47phox-/- mice [165, 578] or by NOX4 siRNA [579]. Thus ROS derived from NOX4, with a possible 
contribution from NOX1, and none from NOX2, may be important in mediating HPV. Considering NOX 
as a possible ROS sensor in HPV, it was suggested that while levels of NOX4 expression in the two 
tissues were not different [67], higher expression of glucose-6-phosphate dehydrogenase in 
pulmonary compared to coronary VSM could support a greater availability of pentose phosphate 
pathway-derived NADPH and NADH during acute hypoxia, resulting in relatively greater NADPH- and 
NADH-dependent NOX-derived ROS production and downstream pro-contractile signalling [580]. 
However, it must now be acknowledged that the primary hypoxic sensor and leading source of any 
change in ROS during acute hypoxia almost certainly originates in the mitochondria. There are two 
key theories in this regard. The first theory is that acute hypoxia reduces the production of 
mitochondrial ROS, resulting in reduced KV1.5 and/or KV2.1 current amplitude, depolarisation and 
enhanced Ca2+ influx [581]. This theory is consistent with the widely observed activation of VSM KV 
currents by ROS in various vascular beds (section 5.5), including pulmonary [351], but does not explain 
the apparent dependence of hypoxic pulmonary vasoconstriction on Rho-kinase mediated Ca2+ 
sensitization [271, 582, 583], RyR mediated Ca2+ release [375, 584, 585] and store-operated Ca2+ influx 
[368, 586]. The second, and perhaps now more widely accepted theory is that hypoxia increases the 
production of mitochondrial ROS [1, 2], permitting the also widely observed ROS-mediated activation 
of Rho-kinase, sarcoplasmic reticulum Ca2+ release and TRP channel mediated Ca2+ influx (sections 4.2-
4.4). A recent study on the effects of cross-transplantation of mitochondria between pulmonary and 
femoral VSMCs supports this, showing that acute hypoxia increases ROS production in native VSMCs 
from both vessel types but does so to a greater extent in pulmonary and that mitochondrial cross-
transplantation fundamentally reverses the differences between pulmonary and femoral ROS 
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production, [Ca2+]i responses and contraction in response to hypoxia [584]. Nevertheless, the theory 
that hypoxia increases ROS production is also compatible with a secondary but potentially important 
role for NOX-derived ROS in HPV, using PKC as a link between the two sources of ROS. This was first 
suggested in perfused rabbit lungs where hypoxia appeared to stimulate PKC-dependent NOX 
activation [587]. It was then shown that PKC- in particular is activated by mitochondrial ROS during 
acute hypoxia in pulmonary VSM, but not in mesenteric, and that PKC- was required for HPV [588]. 
The connection with NOX was then made by showing that acute hypoxia enhanced p47phox dependent 
ROS production, presumably from NOX1, because NOX2 was not expressed, and that this ROS 
production and HPV were suppressed in PKC--/- mice [165], indicating that PKC- activates NOX1 in 
response to mitochondrial ROS by phosphorylating p47phox, as also described for PKC- and PKC- 
(section 2.2). In contrast, this study also showed that hypoxia did not activate either PKC- or NOX in 
mesenteric arteries [165]. Interestingly, Src, another kinase known to be important in the assembly 
and activation of NOX1 or 2, is also activated by acute hypoxia via mitochondrial ROS [174]. There are 
as yet no reports of an involvement of NOX5 in HPV. As an additional effector pathway for ROS induced 
contraction during HPV, K+ channel inhibition by hypoxia-induced, NOX4-derived ROS has been 
suggested [589], perhaps via ROS-induced channel degradation [590], as had been previously claimed 
for GPCR-induced contraction downstream of NOX-derived ROS in pulmonary artery [58, 146]. 
However, this is a relatively infrequently reported phenomenon in a wider context, with the majority 
of studies on KV channels showing them to be activated by ROS, as discussed earlier in this review. It 
remains to be determined whether the inhibition of KV currents by ROS is pulmonary-specific. A 
proposed model for the role of NOX in HPV is summarised in Figure 9.  
 
7.3. Role of NOX in pulmonary hypertension. Pulmonary hypertension (PH) is defined as a mean 
pulmonary arterial pressure in excess of 25mmHg or in excess of 20 mmHg if there are other 
hemodynamic abnormalities present. PH has a number of causes, including idiopathic (genetic and 
pharmacologically induced, also known as pulmonary arterial hypertension, PAH)); and PH due to lung 
disease or chronic hypoxia [591]. There are other categories, but these two are the most widely 
studied, having approximate correlates in animal models. Common features of all types of PH are 
impaired endothelium-dependent relaxation, contractile hyper-responsiveness and vascular 
remodelling. As with systemic hypertension, oxidative stress is a central feature of the underlying 
pathophysiology of PH/PAH [59, 210, 234, 589, 592-599] and antioxidants or drugs that target specific 
sources of ROS, such as NOX, have been suggested as potential therapies for PH [600-604]. 
 
Research on enhanced pulmonary VSM contractility in PH has focussed on the mechanisms of elevated 
[Ca2+]i and the role of RhoA/Rho-kinase, and as far as chronic hypoxia-induced PH is concerned many 
of the pathways implicated in normal physiological HPV, such as KV channel inhibition, increased RyR-
mediated Ca2+ release,  increased LVGCC and TRPC-mediated Ca2+ influx and increased RhoA/Rho-
kinase activity, are also implicated in PH [114, 605, 605-616], as well as NOX-dependent impairment 
of endothelium-dependent relaxation [594, 617]. Some of these studies suggest that many of the 
signalling proteins that respond to NOX-derived ROS in response to acute hypoxia are upregulated in 
chronic hypoxia-induced PH or monocrotaline (MCT)-induced PAH (a model of idiopathic PAH). These 
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include L-type (CaV1.2) and T-type (CaV 3.2) Ca2+ channels [610], RyR2 [611], TRPC1 and TRPC6 [612], 
Ca2+-activated chloride channel (TMEM16A) [613] and RhoA and Rho-kinase [605]. In addition, in 
PASMC from patients with idiopathic PAH, expression of the Ca2+ sensing receptor is increased and 
this has been linked to increased Ca2+ influx via STIM/Orai/TRPC channels [614]. Conversely, 
expression of K+ channels, including KV1.5 and KCNK3 (TASK-1) are down-regulated by chronic hypoxia 
and by mutations in bone morphogenetic protein receptor-2 (BMPR2) a common cause of idiopathic 
PAH in humans [618-621]. Vascular remodelling in PH includes hyper-proliferation and migration of 
VSMC, endothelium and fibroblasts and muscularisation of normally non-muscular arterioles and, 
although oxidative stress is implicated in the pathogenesis of this, there appears to have been 
relatively little targeted research into the ROS-sensitive signalling pathways involved. What can be 
gleaned however is that the main pathways that operate in systemic hypertension, such as PTP 
oxidation [597], growth-factor transactivation [622], Nrf2 suppression [597], and kinases Src [623], 
PYK2 [624, 625], JAK2 [626], FAK [269], ERK [210, 525, 593, 625, 627] and PI3K/AKT [628, 629] all play 
major roles in PH/PAH. What may differ is the role of individual NOX isoforms and how their expression 
and activity is altered to promote remodelling and hyper-contractility. A number of pathways exist 
through which expression of NOX and associated signalling proteins may be altered in PH/PAH. These 
include hypoxia-inducible factor-1 (HIF-1) because it is known to be activated by mitochondrial ROS 
[606, 612, 618, 619, 630, 631], the production of which is increased by hypoxia [1, 2]. Activation of 
HIF-1 by hypoxia may occur via the intermediary ROS-dependent activation of Src [632]. Also, as 
discussed further below, important roles for TSP-1 [633], NFKB [625, 633] and peroxisome proliferator-
activated receptor gamma (PPAR) [625, 633] in regulating NOX expression and associated pulmonary 
vascular remodelling have also been suggested.  
 
Even though one study suggest that NOX1 is poorly expressed in PASMC of large pulmonary artery 
from human donors [210], NOX1 expression is several-fold higher in PASMC from patients with 
idiopathic PAH, particularly females and is further increased by treatment with either the estrogen 
metabolite 16-hydroxyestrone (16-HOE) or 5-HT, both of which have been associated with the 
pathogenesis of PAH in humans [59, 597, 634]. NOX1 expression is also upregulated by chronic hypoxia 
in human pulmonary artery fibroblasts [635]. Only a handful of studies have examined the role of 
NOX1 in animal models of PH/PAH, with occasional conflicting results. Chronic hypoxia induces 
pulmonary NOX1 expression in piglets [594, 617], but it is not altered in new-born lambs with PH 
induced by antenatal ligation of the ductus arteriosus [598]. In rats, chronic hypoxia appears not to 
alter NOX1 expression in pulmonary artery [589, 636] whereas MCT induces a 10-fold increase [593]. 
In the latter model, NOX1 siRNA normalises MCT-induced PASMC ERK phosphorylation, proliferation 
and migration [593]. NOX1 knockout in mice suppresses the increased right ventricular systolic 
pressure and prevents the right ventricular hypertrophy and vascular remodelling induced by chronic 
hypoxia [59]. NOX1-/- also suppresses oxidant stress and PASMC proliferation and reverses suppression 
of Nrf2 activity induced by 5-HT [597]. Curiously, another study shows the opposite of the above, 




NOX2 is also reportedly poorly expressed in PASMC of large pulmonary arteries from human donors 
[210], but unlike NOX1, PH in new-born lambs induced by antenatal ligation of the ductus arteriosus 
is associated with increased NOX2 expression [598]. In one study in rats, PH induced by both MCT and 
chronic hypoxia is associated with increased expression of NOX2 in pulmonary arterioles and in the 
endothelium, and it is suggested that this increase is due to a concomitant decrease in expression of 
caveolin-1 [234]. Alternatively, other studies in rats show that pulmonary NOX2 expression is not 
significantly influenced by chronic hypoxia [589, 596, 636] or MCT [593, 638], but that NOX2 activity 
may instead be increased [596]. Either an increased expression or an increased activity of NOX2 would 
be consistent with the inhibitory effect of gp91ds-tat on Ca2+ influx-independent contraction in 
pulmonary artery from chronic hypoxic rats [596]. It would  also be consistent with the suppressing 
effect of NOX2 knockout on pulmonary constrictor hyper-responsiveness, PDGFR and AKT activation, 
vascular remodelling, increased right ventricular pressure and right heart hypertrophy induced by 
chronic hypoxia in mice [599, 639]. Another study in mice shows that chronic hypoxia does increase 
pulmonary NOX2 expression and suggests that this increase and the associated vascular remodelling 
are dependent on mitochondrial ROS [631]. 
 
In PASMC from idiopathic PAH patients, expression of NOX4 was increased 2.5 fold compared to 
matched controls [59, 629]. In cultured human PASMC, NOX4 expression is increased by chronic 
hypoxia and this is mediated in part by autocrine induction of IGF binding protein-3 [592, 635] or by 
upregulation of TSP-1 expression, increased NFKB activity and suppression of PPAR (a negative 
regulator of proliferation) [625, 633]. In this instance, PYK2 appears to be upstream of NFKB activation 
and the downstream ERK phosphorylation required for proliferation [625]. NOX4 expression in human 
pulmonary artery is also increased by another key mediator of VSMC proliferation, transforming 
growth factor- (TGF-) [52, 210]. In new-born lambs with PH induced by ductus arteriosus ligation, 
NOX4 and p22phox expression is increased [598], and also in this model, cyclical stretch, which may 
exert a stronger influence on the vessel wall during PH, induces NOX4 expression via an increase in 
mitochondrial ROS production and induction of NFKB [640]. In rats, a number of studies show that 
pulmonary NOX4 expression is upregulated by chronic hypoxia [234, 589, 595, 629, 636], MCT [234, 
595, 641], another model of spontaneous PH [595] and by human BMPR2 activation [642], while 
another study finds no significant effect of MCT on pulmonary NOX4 expression in rats [593]. Also in 
contrast to rat studies, in piglets there is apparently no effect of chronic hypoxia on pulmonary NOX4 
expression [594]. In mice, pulmonary NOX4 expression is increased by chronic hypoxia [631, 643], 
chronic intermittent hypoxia (CIH) [639] and MCT [638]. In one of these studies, the enhanced NOX4 
expression and the associated PASMC proliferation required hypoxic induction of HIF-1 [643], while 
in another, it and the associated vascular remodelling were also dependent on mitochondrial ROS, 
suggesting a link between mitochondrial ROS and cytosolic NOX4-derived ROS in PH [631], a parallel 
mechanism to that suggested for the acute HPV response [165, 588].  
 
Of all the NOX isoforms expressed in the pulmonary vasculature, the greatest amount of work has 
been done on the role of NOX4 in the mechanisms of vascular remodelling associated with PH/PAH. 
Human PASMC proliferation induced by chronic hypoxia is suppressed by NOX4 siRNA [592, 627] and 
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the dual specific inhibitor GKT137831 [644]. GKT137831 also inhibits proliferation of these cells 
stimulated by the estrogen metabolite 16−OHE and does so more effectively in PASMC from PAH 
patients [59]. NOX4 siRNA also inhibits proliferation induced by TGF- in human PASMC [210, 592], by 
cyclical stretch in PASMC from new-born lambs with PH induced by ductus arteriosus ligation [598, 
640] and by thrombin and human BMP2 in rat PASMC [642, 645]. Putative NOX4-specific inhibitors 
VCC588646 and VCC202273 also partially prevent pulmonary vascular remodelling induced by MCT in 
rat lung [595]. Interestingly, in this last study, pulmonary NOX4 was found to be expressed primarily 
in adventitial fibroblasts and there is emerging evidence for its contribute to PH through promoting 
fibrosis and arterial stiffening [595, 646]. In terms of downstream signalling, NOX4 contributes to the 
enhanced mTOR, S6K and AKT phosphorylation, cell survival and proliferation observed in PASMC 
from PAH patients [629], and it appears to contribute to human PASMC proliferation in response to 
chronic hypoxia in part via suppression of PPAR expression, suggesting a reciprocal negative 
relationship between NOX4 and PPAR [627]. In rat PASMC, NOX4 appears to act via protein 
stabilization of HIF-2 and induction of plasminogen activator inhibitor-1 [645], while in PASMC from 
new-born lambs with PH induced by ductus arteriosus ligation it acts via NFKB activation [598]. In 
models of PH/PAH, there appears to be no evidence for NOX4 contributing to pulmonary VSMC 
migration, although one may expect this based on its known association with integrins, FAK/ILK and 
migratory stimuli in systemic hypertension [107]. There is also evidence that NOX4 participates in 
aberrant elevated [Ca2+]i in PH by suppressing PASMC KV1.5 current [589] and by enhancing expression 
of TRPC1 and TRPC6 [642]. In stark contrast to the above, two studies in mice show little involvement 
of NOX4 in PH, despite evidence for NOX4 upregulation by chronic hypoxia [631, 643], one showing 
that NOX4-/- only reduces the chronic hypoxia-induced increase in right ventricular systolic pressure 
but has no effect on vascular remodelling [59], and the other showing no effect of NOX4-/- on chronic 
hypoxia-induced increases in pulmonary artery pressure or vascular remodelling [647]. 
 
As with systemic hypertension, this data provides conflicting evidence over the importance of NOX to 
PH/PAH, particularly to the associated vascular remodelling.  The data possibly suggests that there are 
species-dependent differences over which NOX isoform may be most important in PH, perhaps NOX4 
and NOX1 in human and rat, NOX1 and NOX2 in mice, with NOX2 appearing of minimal importance in 
rats and humans and NOX4 possibly of minimal importance in mice. However, evidence also conflicts 
between studies using the same model in the same species, so differences may be explained by the 
use of different output measures, time points and drug delivery methods or different approaches to 
data collection. Interestingly, there is very little evidence of a protective effect of NOX4 in PH, unlike 
in systemic hypertension. This is in line with NOX4 being purely pro-contractile in the healthy 
pulmonary circulation and primarily pro-relaxant in the systemic. However, one recent study raises 
doubts about this too, suggesting that H2O2, probably derived (although not proven) from NOX4, 
exerts a protective effect in parallel with the damaging effects described above [648]. This study 
presented evidence for an enhanced oxidative activation of PKGI in lung tissues from humans with 
PH and an animal model of chronic hypoxia, and that this enhanced activity of PKGI was protective 
via both enhanced VSM relaxation and suppression of vascular remodelling. Clearly more work needs 
to be done to clarify the importance of NOX to the pathophysiology of PH and PAH and if possible 
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determine whether there are specific NOX isoforms that may be most suitable as potential therapeutic 
targets. The potential role of NOX in the pathogenesis of PH/PAH is summarised in Figure 10. 
 
8. Summary and future directions. 
There exists a highly complex network of tightly regulated signalling pathways both upstream and 
downstream of NOX-derived ROS production that operates in subtly different ways for different NOX 
isoforms in the VSM and endothelium of different vascular beds. They respond to a variety of 
hormonal, chemical and mechanical stimuli, to produce a range of physiological responses in the 
healthy vasculature. This includes VSM contraction, endothelium-dependent relaxation, VSM gene 
expression, growth, proliferation and migration. Although much has been done to characterise the 
roles of specific NOX isoforms in these functions, more work is needed to clarify the importance of 
compartmentalisation, particularly of NOX4 and NOX5 which are both expressed in sarcoplasmic 
reticulum and NOX4 in mitochondria and nucleus.  There is extensive but inconclusive, and occasional 
contradictory evidence that expression and activity of NOX isoforms and associated signalling 
pathways are altered in various animal models of hypertension, pulmonary hypertension and 
pulmonary arterial hypertension. A role for NOX-derived ROS in the vascular inflammation that 
underlies many cardiovascular diseases, as well as the role of adventitial NOX, requires further 
investigation. For appropriate therapies to be devised and tested for use in humans, further work is 
needed to clarify the relative importance of specific NOX isoforms in these diseases, particularly NOX4 
which appears to exert both detrimental and protective effects in hypertension and possibly in 
PH/PAH as well. Thus, whether general antioxidants or non-selective and highly selective NOX 
inhibitors prove beneficial in the treatment of hypertension in humans may depend on the relative 
effects of suppressing pathological and protective ROS function as well as their contributions to 
normal vascular homeostasis.       
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Figure 1. Activation of vascular NADPH oxidase-1 and -2 (NOX1/2) by G-protein coupled receptor 
(GPCR) stimulation. Inactive NOX1/2 exist in cell membranes coupled with p22phox. Their activation 
follows a complex series of steps which can be divided into two phases. Phase one: Partial assembly 
and partial activation of the enzyme complex require translocation of regulatory subunits p47phox, 
p67phox and p40phox from the cytosol to the membrane. This is achieved through phosphorylation of 
p47phox, and possibly also of p67phox and p40phox, by multiple protein kinase C (PKC) isozymes and Src. 
PKC- may first need to phosphorylate SM22 before it can phosphorylate p47phox. NOXO1 may 
substitute for p47phox and NOXA1 may substitute for p67phox. Src also phosphorylates cortactin, 
releasing it from the regulatory subunits, thus also supporting translocation. Thirdly, translocation is 
also facilitated through interaction with ezrin-radixin-moesin binding phosphoprotein 50 (EBP50). PKC 
isozymes are activated by GPCR through multiple pathways. Gq activates phospholipase C (PLC) which 
makes inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca2+ release from the 
sarcoplasmic reticulum to activate PKC- or -. DAG also is required for activation of PKC- − − 
and -. G subunits activate phospholipase A2 (PLA2) and phospholipase D (PLD), while PLD also 
requires the small G-protein ARF6. The products of these, arachidonic acid (AA), 
lysoposphatidylcholine (LPC) or phosphatidic acid (PA), also activate PKC- − and -. Src is activated 
directly by G. Alternatively, PKC and Src are capable of activating each other by phosphorylation and 
are both activated by other sources of ROS. Phase two: Full, complete activation of the oxidase 
requires the binding of active Rac to p67phox and the catalytic subunit. Rac activation requires prior 
activation of guanine nucleotide exchange factors (RacGEFs) and these are activated by PIP3 and 
tyrosine phosphorylation by Src, FAK, PYP2 or JAK2. PIP3 is generated by phosphatidyl inositol-3 kinase 
(PI3K) which is primarily activated following transactivation of the epidermal growth-factor receptor 
(EGFR) by Src. Low level ROS produced by the partially active NOX are able to diffuse into the cytosol 
via anion channels or aquaporins and may be sufficient to further activate Src as well as inhibit the 
tyrosine phosphatase SHP2 (inactivates PI3K) and the lipid phosphatase PTEN (degrades PIP3 and PIP2). 
EGFR may also be activated by epidermal growth-factor (EGF) generated by a ROS-activated matrix 
metalloprotease. Finally, full activity of the oxidase is promoted by further phosphorylation by PKC-, 
binding of PIP2 and PIP3 and stabilization by heat-shock protein 90 (HSP90) and protein disulphide 
isomerase (PDI). PDI may form an intermolecular disulphide bond with p47phox. Open arrowheads 














Figure 2. Activation of vascular NADPH oxidase-4 (NOX4) and -5 (NOX5) in vascular cells. NOX4 exists 
in cell membranes as a stable complex with p22phox and at the cell surface requires the additional 
binding of polymerase delta interacting protein 2 (Poldip2), which is associated with integrins and talin 
(not shown) at focal attachments in vascular smooth muscle. This may be sufficient for enzyme activity 
and H2O2 production, but activity may also be stimulated further by G-protein-coupled receptor 
(GPCR)-induced or receptor tyrosine kinase (RTK)-induced production of arachidonic acid (AA), 
activation of Rac or activation of protein kinase C (PKC). NOX4 is also present in the sarcoplasmic 
reticulum, although it is not clear whether or how it responds to cell surface receptor stimulation from 
this location or is simply constitutively active. NOX5 exists in cell membranes and, in endothelium, is 
associated with caveolin, which exerts an inhibitory effect on catalytic activity which in turn may be 
relieved by heat-shock protein 90 (HSP90). NOX5 is primarily activated acutely by an increase in 
intracellular Ca2+ concentration induced by GPCR, primarily via Ca2+ release from the sarcoplasmic 
reticulum (SR), which it senses via four ‘EF hands’ and Ca2+-calmodulin (CaM) binding sites on a long 
intracellular auto-inhibitory domain. Sensitivity of NOX5 to Ca2+ may also be enhanced by 
phosphorylation of the catalytic subunit by PKC-, Ca2+-calmodulin-activated kinase II (CAMK-II) or c-
Abl but may be inhibited by phosphorylation by PKC-. ECM = extracellular matrix. Open arrowheads 










Figure 3. Compartmentalisation and metabolism of NADPH oxidase (NOX) isoforms. All NOX 
isoforms are expressed at the cell surface, but in endothelium NOX1, 2 and 5 are concentrated in 
caveolae (associated with the flow sensing ‘mechanosome’ (M)), while in vascular smooth muscle 
NOX4 is concentrated at focal attachments in association with polymerase delta interacting protein-2 
(Poldip2). Superoxide produced at the cell surface in response to G-protein coupled receptor (GPCR) 
stimulation is extracellular, but can enter the cell through anion channels (AC, either chloride channel-
3 or LRRC8) or be dismutated by extracellular superoxide dismutase (EC-SOD) into H2O2 which can 
enter the cell via aquaporins. Alternatively, all NOX isoforms may be endocytosed with activating 
receptors (eg. receptor tyrosine kinases (RTK) or TNF- receptors (TNFR)). ROS are produced within 
the endosome to influence effector pathways there or can enter the cytosol through anion channels. 
NOX4 is highly expressed in the sarcoplasmic reticulum (SR) where it will influence protein folding and 
possibly Ca2+ handling. H2O2 is free to leave the SR via aquaporins. NOX5 is also expressed in the SR 
and NOX4 is also expressed in the mitochondria and nucleus. In the nucleus, NOX4 may contribute to 
the regulation of gene expression, while the function of NOX5 in the SR and NOX4 in the mitochondria 
is unknown. The main source of mitochondrial ROS is most likely complexes I and III of the electron 
transport chain. These are also free to enter the cytosol through aquaporins and possibly also anion 
channels. Superoxide and H2O2 oxidise cysteine (-SOH) and methionine (-SCHO, not shown) in target 
proteins, either directly or using oxidised PRX as an intermediate. Oxidation of adjacent cysteine 
residues may trigger formation of a disulphide bridge. Nitric oxide (NO∙) modifies cysteine by 
nitrosylation (-SNO). Superoxide and NO∙ combine to form peroxynitrite (ONOO-) which modifies 
proteins through nitration of tyrosine residues (-ONO). Glutathione peroxidase (GPX) uses the main 
intracellular reductant reduced glutathione (GSH) to reduce H2O2, producing oxidised glutathione 
(GSSG). GSSG may also modify proteins through glutathionylation (-SSG). Antioxidant enzymes are 
widely expressed in the cytosol and intracellular organelles where they will limit the accumulation of 
ROS and contribute to the compartmentalisation of ROS signalling. Superoxide is dismutated by SOD1 
in the cytosol, endosomes and mitochondrial outer membrane and by SOD2 in the mitochondrial 
matrix. H2O2 is reduced by cytosolic catalase (Cat) and GPX, by GPX in the mitochondria and by GPX 
and PRX in the SR. GSSG is re-reduced by glutathione reductase, using NADPH (not shown). Open 







Figure 4. Role of NADPH oxidase (NOX) in vascular smooth muscle (VSM) Ca2+ signalling. G-protein 
coupled receptor (GPCR) stimulation activates phospholipase C (PLC, via Gq) and NOX1 or NOX2 on the 
cell surface. PLC generates inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca2+ 
release from the sarcoplasmic reticulum via IP3R while DAG activates protein kinase C (PKC). NOX-
derived ROS induce extracellular Ca2+ influx and Ca2+ release from the sarcoplasmic reticulum via 
multiple pathways. ROS stimulate Ca2+-activated chloride channels (ClCa) and TRPC1/6/Orai, the latter 
probably via stimulation of PKC-dependent phosphorylation. Opening of these channels depolarises 
the cell membrane, thus opening L-type voltage-gated Ca2+ channels (LVGCC). ROS may further 
enhance LVGCC opening through channel phosphorylation by Src, PKC or CAMK-II, or by direct cysteine 
oxidation, but whether the latter is stimulatory or inhibitory is unclear. ROS promote Ca2+ release from 
the sarcoplasmic reticulum by enhancing the sensitivity of IP3R to IP3 and by activating the ryanodine 
receptor (RyR). RyR is also activated by ROS indirectly by displacing the inhibitory protein FKBP from 
RyR and by stimulating CD38, which makes cyclic ADP-ribose (cADPR) and nicotinic acid adenine 
dinucleotide phosphate (NAADP). cADPR further stimulates RyR while NAADP stimulates Ca2+ release 
via the Two-Pore channel (TPC). ROS also help maintain an elevated [Ca2+]i by inhibiting Ca2+ extrusion 
via the plasma membrane Ca2+ ATPase (PMCA) and re-uptake into the sarcoplasmic reticulum via the 
sarco-endoplasmic Ca2+ ATPase (SERCA). Finally, ROS also may stimulate the Na+/Ca2+ exchanger, but 
this may oppose the other effects by extruding Ca2+. NOX4 is expressed in the sarcoplasmic reticulum 
of VSM, but details of its contributions to Ca2+ homeostasis are unknown. Open arrowheads indicate 








Figure 5. Role of NADPH oxidase (NOX) in Ca2+-independent pro-contractile signalling in vascular 
smooth muscle. Contractile force may be enhanced without an increase in [Ca2+]i through two main 
pathways: inhibition of myosin light-chain phosphatase (MLCP) and actin polymerisation. MLCP is 
negatively regulated by Rho-kinase (ROCK) through inhibitory phosphorylation of myosin phosphatase 
regulatory subunit-1 (MYPT1). ROCK is activated by RhoA. RhoA is either activated directly by 
superoxide or by Rho guanine nucleotide exchange factors (RhoGEFs). RhoGEFs are activated by G-
protein coupled receptors (GPCR) either directly via G12/13, or indirectly by NOX1- or NOX2-dependent 
tyrosine phosphorylation by Src, PYK2 or JAK2. RhoGEFs are also activated by stretch via integrin 
engagement with extracellular matrix (ECM) and subsequent activation of focal adhesion kinase (FAK), 
in association with H2O2 produced by NOX4 coupled to polymerase delta interacting protein-2 
(Poldip2).  RhoA promotes actin polymerisation either directly or indirectly by promoting ROCK and 
LIM kinase (LIMK)-induced inhibition of the actin severing protein cofilin. Additional routes for the 
promotion of actin polymerisation are by direct oxidation of actin by NOX4-derived H2O2, inhibition of 
the actin chaperone heat-shock protein 27 (HSP27) by p38 MAP-kinase and MAP-kinase activated 
protein kinase (MAPKAP) and ERK MAP-kinase-mediated inhibition of caldesmon which inhibits actin-
myosin cross-bridge cycling. p38 and ERK MAP-kinases are both activation by ROS via MEK. NOX-
derived H2O2 activates MEK via Src-dependent transactivation of receptor tyrosine kinases (RTK) and 
subsequent recruitment of growth-factor receptor binding protein-2 (GRB2), Ras and Raf, by direct 
oxidation of Ras, by oxidative inhibition of a MEK phosphatase or via protein kinase C (PKC) directed 
phosphorylation. PKC also inhibits MLCP by activating the inhibitory accessory protein C-kinase 
potentiated protein phosphatase-1 Inhibitor-17 (CPI-17). Open arrowheads indicate movement or 








Figure 6. Role of NADPH oxidase (NOX) in endothelium-dependent relaxation of the vasculature. 
NOX1, 2, 4 and 5 are all expressed in the endothelium and 1, 2 and 5 are present in the caveolae. All 
isoforms are activated by pro-relaxant G-protein coupled receptor (GPCR) agonists and by flow via the 
endothelial flow ‘mechanosome’. In caveolae, this consists of VEGFR, VE-cadherin and PECAM-1 and 
is associated with closure of KATP and opening of T-type Ca2+ channels (not shown). Caveolin-1 acts as 
a negative regulator of NOX1, 2 and 5 but this inhibition can be relieved by HSP90. The mechanism of 
NOX4 activation by GPCR and the exact nature of the NOX4 flow sensor are unclear. NOX4 generates 
H2O2 while NOX1/2/5 make superoxide, some of which is dismutated to H2O2 by SOD in the 
endothelium. GPCR also raise endothelial [Ca2+]i by triggering release from the sarcoplasmic reticulum 
via IP3R and RyR, and this Ca2+ stimulates eNOS to make NO∙, which diffuses to the vascular smooth 
muscle (VSM) to activate guanylate cyclase (GC). GC makes cGMP which activates protein kinase G 
(PKG). PKG phosphorylates and activates large conductance Ca2+-activated K+ channels (BKCa) to 
hyperpolarise the VSM, lower [Ca2+]i and induce relaxation by closing L-type voltage-gated Ca2+ 
channels (LVGCC). Endothelial ROS, principally from NOX4, further promote eNOS activity by activating 
kinases which phosphorylate eNOS and by further raising endothelial [Ca2+]i by enhancing Ca2+ release 
via RyR and Ca2+ influx via TRPA1 channels. VSM Endothelial Ca2+ (enhanced by H2O2) also activates 
the small and intermediate conductance Ca2+-activated K+ channels (SKCa and IKCa). The extruded K+ 
diffuses to the VSM and activates the Na+/K+ATPase and inward rectifier (KIR) channels to hyperpolarise 
the VSM, while endothelial hyperpolarisation may also spread to the VSM via myo-endothelial gap 
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junctions (MEGJ). NOX4-derived H2O2 and any dismutated superoxide from NOX1, 2 or 5 also acts as 
a direct hyperpolarising factor. It diffuses to the VSM where it directly activates BKCa and voltage-gated 
K+ channels (KV), further activates GC and PKG and activates MAPK to further stimulate KV channels, 
thus further hyperpolarising the VSM. Superoxide derived from endothelial NOX1, 2 and 5 partly 
antagonises eNOS by oxidising BH4, thus uncoupling eNOS, forcing it to make more superoxide. 
Conversely, NO∙ also limits superoxide production by inhibiting the activity of NOX1, 2 and 5. NO∙ and 
superoxide react to make ONOO-. In the VSM, this promotes formation of oxidised glutathione (GSSG) 
which may activate SERCA, enhancing the rate of VSM Ca2+ uptake into the sarcoplasmic reticulum, 
thus promoting relaxation. H2O2 may also directly inhibit LVGCC. VEGFR = vascular endothelial growth-
factor receptor, PECAM-1 = platelet-endothelial cell adhesion molecule-1, HSP90 = heat-shock protein 
90, SOD = superoxide dismutase, EC-SOD = extracellular SOD, IP3R = inositol trisphosphate receptor, 
RyR = ryanodine receptor channel. Open arrowheads indicate movement or production of a 









Figure 7. Proposed role of vascular NADPH oxidase (NOX) in the pathogenesis of hypertension. 
Multiple mitogenic and pro-contractile stimuli (Ang II, ET-1, PDGF, TNF-) induce an increased vascular 
expression of NOX1, NOX2, regulatory subunits p22phox (p22), p47phox (p47), p67phox (p67) and NOXA1, 
and NOX5. Vascular NOX1 and NOX2 expression are also increased in the spontaneously hypertensive 
rat (SHR). NOX5 activity may be suppressed by polymorphisms in humans, while activity of p22phox may 
be increased (not shown). NOX4 expression is upregulated by inflammatory mediators (eg TNF-) and 
mechanical forces associated with cardiovascular disease: oscillatory flow in endothelium (EC) and 
elevated perfusion pressure in vascular smooth muscle (VSM). Most studies agree that NOX4 
expression is enhanced in SHR and in Ang II-induced hypertension, and this may be via inhibition of 
BCL6 expression, thus relieving BCL6-induced suppression of NOX4 expression. NOX4 expression may 
also be enhanced by chronic intermittent hypoxia (CIH). Collectively, the result of enhanced NOX 
expression is the production of excess superoxide (O2∙-, NOX1, NOX2 and NOX5) and H2O2 (NOX4), 
resulting in oxidant stress. Accumulation of superoxide may be exacerbated by reduced expression or 
activity of superoxide dismutase (SOD). Oxidant stress impairs endothelium-dependent relaxation 
through the combined effects of NO∙ scavenging and eNOS uncoupling. Excess superoxide also impairs 
guanylate cyclase (GC) activity. Vascular hyper-contractility is further exacerbated by elevated VSM 
[Ca2+]i, through suppression of SERCA activity, enhanced Ca2+ release from the sarcoplasmic reticulum 
and elevated Ca2+ channel activity, and through increased expression and activity of RhoA and Rho-
kinase (ROCK). Vascular remodelling occurs through the combined action of ROS-stimulated VSMC 
migration (mediated by FAK, ILK, integrins and RhoA/ROCK), proliferation (primarily ERK MAP-kinase 
mediated, MAPK), increased survival (PI3K and AKT mediated) and fibrosis, coupled to inflammation. 
These processes are promoted by oxidative inhibition of protein tyrosine phosphatases (PTP) and 
enhanced activity of non-receptor tyrosine kinases (NRTK) and receptor tyrosine kinases (RTK). The 
NRTKs FAK, Src, PYK2 and JAK2 as well as protein kinase C (PKC) are all essential co-ordinators of 
vascular remodelling (see Figure 8 for more details). They also promote hyper-contractility via 
RhoA/ROCK. VSM proliferation and fibrosis is also supported by oxidative activation of the 
transcription regulator nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB).  
Opposing the ‘oxidant stress’ effects of enhanced NOX4 expression, excess H2O2 may also have a 
protective effect in hypertension, via activation of nuclear factor erythroid 2-related factor 2 (Nrf2), 
which may act to improve endothelial function and maintain a differentiated VSM phenotype. TNF- 
= tumor necrosis factor- PDGF = platelet derived growth factor. Open arrowheads indicate 









Figure 8. Role of NADPH oxidase (NOX) in vascular smooth muscle growth, proliferation and 
migration in response to G-protein coupled receptor activation and stretch. NOX1, 2 or 5 in the 
plasma membrane or endosomes are activated by G-protein coupled receptor (GPCR) agonists. The 
ROS generated produce parallel inhibition of multiple protein tyrosine phosphatases (PTPs), and 
activation of multiple non-receptor tyrosine kinases (Src, PYK2 and JAK2), CAMK-II and PKC. One 
consequence of this is Src-mediated transactivation of receptor tyrosine kinases (RTKs) which act as 
platforms for the parallel activation of PI3K, Ras and PLC-. PI3K activates AKT and mTOR and 
downstream protein synthesis and cell survival responses via S6K and 4EBP. Via GRB2, Ras activates 
Raf, MEK and ERK MAP-kinase (ERK) to promote cell division and proliferation. Alternatively, Raf and 
MEK activation occur via CAMK-II-mediated or PKC/PYK2/JAK2-mediated phosphorylation. Nuclear 
translocation of ERK is supported by Rho-kinase (ROCK). PLC- triggers Ca2+ release from the 
sarcoplasmic reticulum, which activates PYK2 and then JAK2. JAK2 also supports proliferation via STAT 
and ERK. In addition, Src promotes activity of the pro-proliferative transcription regulator NFKB via 
inhibition of IKB. p38 MAP-kinase (p38) is also involved in stimulating proliferation downstream of 
MEK or TRAF2/ASK, and contributes to the activation of NFKB, particularly in response to TNF- 
receptor activation. Both p38 activation pathways are NOX-dependent (not shown). As a braking 
mechanism to this, ROS also promote activity of the cyto-protective transcriptional regulator Nrf2 via 
degradation of the inhibitory KEAP1. Via Src, GPCR-induced ROS may also activate FAK at focal 
adhesions. This may lead to ‘inside-out’ activation of integrins and activation of NOX4. Alternatively, 
stretch may activate integrins leading to ‘outside-in’ activation of FAK and NOX4. Either way, activated 
FAK also acts as a platform for the GRB2/Ras proliferation pathway and the PI3K/AKT growth and cell 
survival pathway, while FAK and NOX4-derived ROS will promote actin polymerisation/de-
polymerisation, focal adhesion turnover and migration via ILK/paxillin and RhoA, Rac and cofilin 
activity. CAMK-II also promotes migration via Rac or MMP9. NOX4 in the mitochondria or nucleus and 
NOX4 and NOX5 in the sarcoplasmic reticulum may also contribute to these responses through as yet 
uncharacterised pathways (not shown). CAMK-II = Ca2+-calmodulin activated kinase-II. PYK2 = protein 
tyrosine kinase-2.  JAK2 = Janus kinase-2. MMP9 = matrix metalloprotease-9. PKC = protein kinase C. 
PI3K = phosphatidyl inositol-3 kinase. mTOR = mammalian target of rapamycin. S6K = S6-kinase. 4EBP 
= eukaryotic translation initiation factor 4E-binding protein. GRB2 = growth-factor receptor bound 
protein-2. PLC- = phospholipase C-. STAT = signal transducer and activator of transcription. NFKB = 
nuclear factor kappa-light-chain-enhancer of activated B cells. ASK = apoptosis signal-regulating kinase 
1. IKB = inhibitor of KB. Nrf2 = nuclear factor erythroid 2-related factor 2. Poldip2 = polymerase delta 
interacting protein-2. FAK = focal adhesion kinase. ILK = integrin-linked kinase. RhoGEFs = Rho guanine 
nucleotide exchange factors. S1L = Slingshot-1L. Double-headed arrows indicate a bi-directional 
activation pathway. Open arrowheads indicate movement or production of a substance. Closed 








Figure 9. Proposed model for the role of NADPH oxidase (NOX) in hypoxic pulmonary 
vasoconstriction (HPV). Hypoxia may preferentially activate NOX4 by increasing the availability of 
cytosolic NADPH and NADH and/or by triggering an increased production of ROS from the 
mitochondrial electron transport chain (ETC) which activate PKC- and/or Src to phosphorylate 
regulatory subunits of NOX1 (PKC and Src) and directly phosphorylate NOX4 (PKC only). NOX-derived 
ROS may then raise [Ca2+]i through a combination of KV channel inhibition, TRPC/Orai store-operated 
Ca2+ channel opening and subsequent L-type voltage-gated Ca2+ channel opening (LVGCC). TRPC 
channel opening may be further stimulated via ROS-dependent activation of the Ca2+-sensing receptor 
(CaSR). ROS also trigger Ca2+ release from the sarcoplasmic reticulum through ryanodine receptor 
channels (RyR) via enhanced production of cyclic ADP-ribose (cADPR). It is not known whether NOX4 
in the sarcoplasmic reticulum contributes to this. Ca2+ activates myosin light-chain kinase (MLCK) to 
phosphorylate myosin light-chain-20 (MLC20) and trigger contraction. In parallel to an increase in 
[Ca2+]i, ROS may also inhibit myosin light-chain phosphatase (MLCP) activity to further enhance MLC20 
phosphorylation. This most likely occurs via Rho-kinase-dependent inhibitory phosphorylation of 
MYPT-1, and ROS most likely activate Rho-kinase via direct activation of RhoA or via Src-dependent 
phosphorylation of Rho guanine nucleotide exchange factors (RhoGEFs). Open arrowheads indicate 











Figure 10. Proposed role of vascular smooth muscle NADPH oxidase (NOX) in the pathogenesis of 
pulmonary hypertension (PH) and/or pulmonary arterial hypertension (PAH). Multiple mitogenic 
and pro-contractile stimuli induce the increased expression of NOX1, NOX2 and/or NOX4. Chronic 
hypoxia and cyclical stretch act via mitochondrial ROS, the induction of HIF-1 and NFKB and 
suppression of PPAR Oxidant stress probably induces pulmonary arterial hyper-contractility through 
the combined effects of reduced NO∙ bioavailability, elevated [Ca2+]i, through suppression of K+ 
channel expression and elevated Ca2+ channel expression, and enhanced RhoA/Rho-kinase expression 
and activity. Vascular remodelling occurs through the combined action of ROS-stimulated VSMC 
migration, proliferation, increased survival and fibrosis. These processes are promoted and co-
ordinated by oxidative inhibition of protein tyrosine phosphatase (PTP) activity and enhanced activity 
of non-receptor tyrosine kinases (NRTK) and receptor tyrosine kinases (RTK). Counter to the 
pathogenic effects of oxidant stress, there may also be an underlying protective effect via activation 
of protein kinase G-1 (PKGI) which may promote relaxation and suppress remodelling. MCT = 
monocrotaline, CIH = chronic intermittent hypoxia, 16-HOE = 16-hydroxyestrone, 5-HT = 5-
hydroxytryptamine, BMPR2 = bone morphogenetic protein receptor-2, TSP-1 = thrombospondin-1, 
IGFBP3 = IGF binding protein-3, HIF-1 = hypoxia-inducible factor-1, HIF-2 = hypoxia-inducible 
factor-2 NFKB = nuclear factor kappa-light-chain-enhancer of activated B cells, PPAR = peroxisome 
proliferator-activated receptor gamma, Nrf2 = nuclear factor erythroid 2-related factor 2, Cav-1 = 
caveolin-1, ROCK = Rho-kinase, Open arrowheads indicate movement or production of a substance. 





Table 1. Effects of vasoactive and mitogenic stimuli on ROS production in vascular tissues and cells. 
DHE = dihydroethidium, DCF = 2,7-dichlorofluorescein. Note that in many of the publications cited 
here DHE, LO-12 and Lucigenin are nominally used as selective probes for superoxide, while DCF and 
Amplex Red are nominally assumed to be selective for extracellular and intracellular H2O2 respectively. 
However, for some probes the accuracy and validity of this assumed selectivity may depend on the 
sample preparation and detection methods use [649]. VSMCs = vascular smooth muscle cells. 
stimulus Species and vascular bed Indicator(s) Effect(s) reference 
Intact Tissue 
Angiotensin II Mouse aorta 
Mouse renal afferent arterioles  
Rat and mouse mesenteric artery 




cytochrome C reduction 
Increased 
superoxide 
[89, 94, 98, 101, 101, 104, 106] 
Rat cerebral artery Mouse renal afferent 




Increased  H2O2 [82, 99, 105, 325, 377]  
Prostanoids Mouse aorta 
Mouse mesenteric artery  
Bovine coronary artery  
Rat pulmonary artery 
L-012 Increased 
superoxide 
[66, 140, 140, 174] 
sphingosylphosphoryl
choline 
Mouse Mesenteric C-DCFH/DA Increased  H2O2 [148] 
Other GPCR agonists Rat tail artery 
Human coronary artery 
Rat or mouse pulmonary artery 





[113, 114, 135, 138, 178] 
 
Perfusion pressure & 
stretch 
 
Mouse afferent arterioles 
Rat femoral artery 
Bovine coronary artery 








[162, 194, 334, 353] 
 
Mouse afferent arterioles 
 
DCF Increased  H2O2 [230, 327] 
Flow/ shear-stress Mouse cerebral arteries (endothelium in situ)  
Human coronary arterioles (endothelium in 
situ) 
DCF Increased  H2O2 [408, 418] 
Flow overload 
Flow reversal 















Porcine, mouse and rat  pulmonary artery  
 
DCF Increased  H2O2 [588, 589, 650] 
     




Mouse and rat Aortic VSMC 
Rat renal afferent arteriole VSMCs 
Human resistance vessel VSMCs 
Bovine pulmonary artery VSMCs 
DHE,  
Electron spin resonance 
spectroscopy 
Lucigenin 
Cytochrome C reduction 
Increased 
superoxide 
[72, 75, 80, 90, 95, 108, 133, 157, 163, 169] 
 
Rat aortic VSMCs 
Human aortic VSMC  
Human resistance vessel VSMCs 
Human coronary artery SMCs 
Human VSMC cell line 
DCF 
Amplex red 




Bovine pulmonary artery SMCs  
Rat aortic VSMCs 
Mouse and bovine pulmonary VSMC 






[58, 142, 147-149] 
Rat aortic VSMCs 
Rat pulmonary VSMC 






Other GPCR agonists 
 
Rat and mouse aortic VSMCs 






[109, 117, 125, 126, 152] 
 
Rat and mouse aortic VSMCs 
Human coronary artery myocytes 
DCF Increased  H2O2 [116, 121, 130, 136, 225] 
Cytokines and growth-
factors 
Mouse, rat and human aortic VSMC Lucigenin, DHE, LO-12 
H2FF-BSA (endosomal 
specific)  










Mouse and rat aortic VSMC 
Human pulmonary VSMC 
DCF  
Homovanillic acid assay 
FAT-HyPer (focal adhesion 
targeted  H2O2 probe) 
Increased  H2O2 [130, 163, 187, 203, 210, 267] 
 
stimulus Species and vascular bed indicator effect reference 
Endothelium 
Angiotensin II Mouse aortic ECs 
Human skin microvascular ECs 
 Human coronary microvascular ECs 
DHE 









Mouse mesenteric ECs 
Rat femoral artery ECs 
Human umbilical vein Cs  
Human and bovine aortic ECs  
Bovine pulmonary ECs 
Porcine aortic ECs 
DCF Increased H2O2 [237, 402, 405, 416, 417] 
Other GPCR agonists HMEC-1 (cell line) 





[55, 124, 144, 232] 
Laminar  shear-stress 
 
Rat basilar artery ECs  
Bovine aortic ECs 
DHE 
Cytochrome C assay 





Bovine aortic ECs DCF, pHyper Increased  H2O2 [414] 
Laminar  shear-stress  
(prolonged) 





oscillatory  shear-stress 
or cessation of flow 
 
Human umbilical vein ECs 
Mouse and bovine aortic ECs 
DHE 
electron spin resonance 
Increased 
superoxide 
[414, 419, 431, 443, 652] 
 
Mouse lung capillary ECs  
Mouse pulmonary artery ECs  
Mouse and bovine aortic ECs 
DCF  
Amplex red 
Increased  H2O2 [431, 432, 444] 
Cytokines and growth 
factors 
Mouse and human pulmonary ECs  
Human umbilical vein ECs 
Fe2+ oxidation xylenol 
orange 
Amplex Red 
Increased  H2O2 [52, 158, 221, 223] 
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Table 2. Effects of antioxidants and NOX inhibition on vascular smooth muscle contraction 
responses to GPCR agonists, pressure and hypoxia and on relaxation responses to GPCR agonists 
and flow/shear stress. Note that drugs commonly used as non-selective NOX inhibitors, particularly 
diphenyleneiodonium (DPI) and apocynin are no longer considered selective enough for NOX and may 
indeed simply be acting as antioxidants [337], so any results with these drugs should be supported 
with the use of more selective drugs or specific NOX isoform siRNA or knockout. NaC = N-acetyl 




vascular bed  
Inhibitor and effect Target Inferred role of Target Reference 






Rat cerebral  
Mouse mesenteric 
Mouse renal afferent 
arterioles 
Rat pulmonary artery 










ROS, NO1 and NOX2 = Pro-contractile [89, 99, 104, 105, 133, 





Rat  Tail artery 
Tiron, NaC, apocynin, VAS2870 
catalase, Poldip2+/- all inhibit contraction 
ROS 
NOX4 
ROS and  NOX4 = Pro-contractile [131, 135, 226] 
ET-1-induced 
contraction 
Rat pulmonary artery 
Mouse mesenteric 
artery 
Tiron  N-Acetyl cysteine  
Both inhibit contraction 





Rat mesenteric artery Tempol, VAS2870  -inhibit 
p47phox-/- -inhibits but gp91phox -/- has no effect 
ROS 
NOX1 
NOX1 = Pro-contractile but NOX2 is not [148] 
U46619-induced 
contraction 
Bovine coronary artery   
Mouse mesenteric 
artery 
Rat pulmonary artery 
NaC Peg-catalase,  Tempol, ebselen,  
apocynin, DPI  
gp91-ds-tat,  
NOX2-/-, p47phox-/-  
All inhibit contraction 
ROS 
NOX2 




Mouse aorta Apocynin, PEG-SOD/Cat 
All inhibit contraction 
ROS  
NOX  
NOX = Pro-contractile [116] 
5-HT-induced 
contraction 
pulmonary (mouse) SOD, apocynin 
Both inhibit contraction but 
gp91phox -/- has no effect 
Superoxide  
Not NOX2 
Superoxide = Pro-contractile 
Not NOX2-derived 
[138] 





Mouse renal afferent 
arterioles  
 
PEG-SOD, tempol, ebselen, apocynin,    
p47phox -/- 
All inhibit contraction 
superoxide 
NOX1 or 2 
NOX1/2 = Pro-contractile [99, 104, 230, 327, 334] 
POLDIP2+/-. PEG-catalase 
Both inhibit contraction 




Bovine coronary artery 
Bovine pulmonary artery 
Apocynin, DPI, ebselen 
All inhibit contraction 
ROS  
NOX 
NOX = Pro-contractile [194, 353] 






Mouse pulmonary artery Apocynin, p47-/- 
P47 translocation inhibitor 
NOX, ROS NOX contributes to HPV [165] 
Porcine and guinea-pig 
pulmonary artery 
SOD inhibits  
DETCA (SOD inhibitor) potentiates 
superoxide Superoxide contributes to HPV [650, 653] 
Mouse and bovine 
pulmonary artery 
gp91phox -/- no effect 
p47phox -/- partial inhibition 
NOX1 NOX1 but not NOX2 contributes to HPV [578] 
NOX2 siRNA –no effect 
NOX4 siRNA –partial inhibition 
NOX2 
NOX4 




Stimulus Species and 
vascular bed 










Rat aorta  
Mouse mesenteric 
artery  
Cat cerebral artery Dog 
coronary artery 
Rat femoral artery 
SOD restores impaired relaxation  
 
Catalase, eNOS -/- inhibit relaxation 
 
H2O2 H2O2 = Pro-relaxant 
 
(eNOS-derived)  H2O2 = Pro-relaxant 




NOX1-/- improved relaxation NOX1, ROS NOX1 = Pro-contractile [424] 
Aorta from renovascular 
hypertensive mice 
NOX2 -/-, gp91ds-tat, Tiron, PEG-SOD  
All restore impaired relaxation 
NOX2 NOX2 = pro-contractile 
 
[425] 
Perfused cerebral artery 
from mouse 
PEG-cat/gp91ds-tat 
Both inhibit relaxation 
NOX2/ H2O2 NOX2 = Pro-relaxant [418] 
Mouse aorta and 
perfused heart 
 
Endothelium-specific NOX4 over-expression 
enhances relaxation and reduces perfusion 
pressure 
NOX4,  H2O2 
(not 
superoxide) 
NOX4 = Pro-relaxant [215] 
Mouse mesenteric 
artery 
Human NOX5 expression in VSM 
Inhibits relaxation 







SOD-/- inhibits increased flow)Catalase 
inhibits hyper-polarisation and relaxation 
H2O2 H2O2 = Pro-relaxant [404, 438] 
Adenosine-
induced relaxation 
Rat cerebral artery PEG-SOD, PEG-Cat ROS ROS = pro-relaxant [117] 
Histamine-
induced relaxation 
Mouse aorta and 
perfused heart 
 
EC-specific NOX4 over-expression 
enhances relaxation response and reduces 
perfusion pressure 
H2O2  NOX4 = Pro-relaxant 
H2O2 = Pro-relaxant 
[215] 




Human coronary artery 
Rat mesenteric artery 
Human coronary 
arterioles 
Mouse cerebral arteries 
Catalase, PEG-catalase  
gp91ds-tat 
All inhibit relaxation 
H2O2 H2O2 = pro-relaxant 
NOX2 = pro-relaxant 
[408, 410, 411, 418] 
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Table 3. Effects of exogenous reactive oxygen species (ROS) on vascular tone. Pro-contractile and 
pro-relaxant effects of H2O2 or superoxide (generated extracellularly with xanthine/xanthine oxidase 




Pro-contractile effects of ROS 
ROS stimulus Pre-constriction? Vascular bed Bath 
conc. 




None Rat aorta and pulmonary artery 1-400µM Causes contraction [311, 339, 340] 
PGF2 
U46619/L-NAME 
Rat pulmonary artery, mesenteric 
artery and femoral artery 
1-10µM Enhances pre-constriction [174, 311, 351] 
Pressure/myogenic Mouse renal afferent arteriole 
Rat cerebral artery 
0.1-250µM Enhances pre-constriction [325, 327] 
KCl Rat pulmonary and ,mesenteric 
artery 
1-10µM Enhances pre-constriction [148, 351] 
Permeabilised, pCa 6.9 Rat pulmonary artery 10µM Enhances pre-constriction [311] 
H2O2 
 
None Rat and mouse aorta 
Rat mesenteric artery 
Bovine coronary artery 
Canine cerebral artery 
SHR carotid artery 
Mouse carotid artery  





Causes contraction [131, 146, 194, 283, 326, 340-
342, 342, 343, 343-348, 515] 
phenylephrine Rat mesenteric artery 10-100µM 
 
Enhances pre-constriction [350] 
Pressure/myogenic Rat mesenteric artery 100µM Enhances pre-constriction [343] 
KCl Mouse aorta 
Mouse mesenteric artery 




Enhances pre-constriction [341, 341, 342, 342, 342, 352-
354] 
 
Pro-Relaxant Effects of ROS 
ROS stimulus Pre-constriction? Vascular bed Bath 
conc. 








Rat mesenteric and femoral artery 
Rat aorta 
10-50µM Causes relaxation  [311, 333, 351] 










Mouse, rat and human mesenteric 
artery 
Porcine  coronary artery 
Human coronary arteriole Rat 
femoral artery 
Rabbit iliac artery 
1µM-10mM Causes relaxation [336, 350, 354, 400-407] 
Pressure 
 
Coronary circulation in vivo 1-300µM Increases blood flow [336] 
Myogenic Mouse renal afferent arteriole 
Human coronary arterioles 
Mouse mesenteric artery 
Rat coronary artery 
1µM-1mM 
25µM 
Causes relaxation  [327, 334, 354, 408-411] 
Hypoxia Guinea-pig pulmonary artery 10-300µM 
 
Causes relaxation  [653] 
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Table 4. Effects of antioxidants and NOX inhibition on VSM growth/proliferative/migration & 
associated signalling in response to mitogenic and hypertensive stimuli. DPI = diphenyleneiodonium. 
NaC = N-acetyl cysteine. SOD = superoxide dismutase. 
stimulus Species and 
vascular bed 




Angiotensin II  induced 
proliferation 
 
Mouse and rat aortic 
VSMC  




NOX1 siRNA  
NOX1-/- 
NOX2 siRNA 
All inhibit proliferation 
NOX1/2 NOX1 and NOX2 = pro-
proliferative 
[79, 107, 490, 560] 
Aorta (mouse) NOX4 over-expression  
Does NOT influence proliferation 
NOX4/ H2O2 NOX4  is not pro-proliferative [215] 
Other GPCR agonists 
(Thrombin, ATP, Urotensin 
II, 5-HT) 
Induce proliferation 
Rat and human aortic 
VSMC 






All inhibit proliferation  
NOX 
NOXA1 
NOXA1 = pro-proliferative 
NOX1 = pro-proliferative 
 NOX4 = pro-proliferative 
[118, 121, 126, 127, 597, 
645] 
Growth factors (PDGF,  
TGF-) 
Induce proliferation 





NOX4 siRNA  
NOX5 siRNA 
All inhibit proliferation 
ROS 
NOX5 
NOX4 = pro-proliferative  
NOX5 = pro-proliferative 
[187, 210, 267, 317] 
Chronic hypoxia 








NOX2-/-   
NOX4 siRNA 
GKT137831  





NOX1, NOX2 and NOX4 promote 
pulmonary vascular remodelling 
and PH 






No effect on pulmonary vascular 
remodelling 
NOX4 NOX4 NOT involved in vascular 




Rat pulmonary VSMC NOX1 siRNA  
VCC588646 and VCC202273  
All inhibit proliferation 
NOX1  
NOX4 
NOX1 and NOX4 promote VSMC 
proliferation and remodelling 
[593, 595] 
Other models of PAH  
Induced VSMC proliferation 
Human pulmonary 
VSMC  
Lamb pulmonary VSMC 
Rat pulmonary VSMC 
NOX4 siRNA  
GKT137831 
Inhibit proliferation 
NOX4 NOX4 = pro-proliferative [59, 210, 629, 642] 
RTK transactivation and ERK phosphorylation 
Angiotensin II Rat aortic VSMCs Nac, Tiron, -tocopherol, DPI 
P22phox siRNA 
All inhibit EGFR transactivation and ERK 
phosphorylation 
NOX, ROS NOX = pro-proliferative [90, 95, 103, 274, 560] 








transactivation and/or ERK 
phosphorylation 
Rat and mouse aortic 
VSMCs 
NAC,   Tiron catalase, DPI, apocynin 
dom neg p47 
NOX1-/- and NOX1 siRNA 




NOX1 = pro-proliferative [64, 109, 110, 121, 125, 
130, 136, 147, 149, 156] 
Growth factors (PDGF,  
TGF-) 
Induce  ERK 
phosphorylation 
Rat aortic VSMCs 
Human pulmonary 
VSMC 
Catalase or NaC  
NOX4 siRNA 
 
Inhibit ERK phosphorylation 
NOX4 NOX4 = pro-proliferative [210, 267] 
stretch Bovine coronary artery Ebselen,  DPI, apocynin 
Inhibit EGFR transactivation and ERK 
phosphorylation 
ROS/NOX NOX = pro-proliferative [194] 
VSM Hypertrophy 
Angiotensin II 
Induced VSMC hypertrophy 
Rat and mouse aortic 
VSMCs 
NaC, DPI,  
 p22phox  antisense 
NOX1 siRNA 
 All inhibit hypertrophy 









NOX1/2/4 promote growth [552] 
PI3K/AKT signalling and protein synthesis 
Angiotensin II Human resistance artery 
VSMCs 
Rat aortic VSMCs 
DPI  
NOX1 siRNA 
Inhibit  AKT phosphorylation and protein 
synthesis 
NOX1 NOX1 promotes growth [79, 107] 




Rat aortic VSMCs NAC,  ebselen, Apocynin, DPI  
NOXA1 shRNA 
Inhibit PI3K activation, AKT activation and 
protein synthesis 
NOX1 NOX1 and NOXA1 promote 
growth 
[109, 126, 136, 150] 
VSMC Migration 
Angiotensin II 
Induced VSMC migration 
 
Human coronary artery 
SMCs 





NOX1 NOX1 stimulates migration [100, 107, 560] 




Induced VSMC migration 
Rat  aortic VSMCs 




 (inhibits migration) 
NOX1 NOX1 stimulates migration [125, 147, 178] 
Growth factors (PDGF,  IGF, 
TNF-) 
Induce  VSMC migration 




NOX4 siRNA, POLDIP2 siRNA 




NOX1 and NOX4 stimulate 
migration 
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